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ABSTRACT 
The Development of Gold Nanoparticle Conjugates for the Intracellular 
Delivery of Paclitaxel 
by 
Jacob Gibson 
The following work describes our efforts toward the development of a novel gold 
nanoparticle (AuNP) system capable of the quantitative intracellular delivery of the 
known chemotherapeutic, paclitaxel. The synthetic strategy employed here features the 
covalent grafting of multiple drug molecules to the surface of individual gold 
nanocrystals measuring 2 nm in diameter. This core-shell approach is advantageous as it 
allows for structural analysis based on traditional analytical techniques and, therefore, 
definitive confirmation of chemical structure. Perhaps more importantly, the ability to 
manufacture such a well-defined delivery system allows one to more accurately quantify 
the amount of bound drug and ultimately, biological activity. While varying the linker 
structure results in analogous paclitaxel-AuNP conjugates capable of drug release based 
on endogenous biological processes, a study of the inherent intracellular behavior of 
these gold nanoparticles led to the discovery of a specific functionality required for 
efficient drug dissociation under cellular conditions. In fact, results from cell culture 
experiments reveal this novel delivery system as having comparable toxicity to that of the 
parent drug, while demonstrating a marked reduction in systemic toxicity in animal 
models. 
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Chapter 1: Introduction 
1.1. Encapsulation Method Towards Hydrophobic Drug Delivery 
Recent work in the area of hydrophobic drug delivery has been focused on the 
development of various objects capable of sequestering and delivering biologically active 
materials to specific disease sites in the body. Strategies include the association of 
hydrophobic compounds within the core of polymeric micelles, dendrimers, as well as 
other various self-assembled entities, and have been successful in improving the 
administration and bioavailability of hydrophobic materials in the body.1"5 Further, the 
ability to incorporate targeting moieties onto the surface of these delivery systems has 
been shown to promote increased interaction with specific targets, resulting in a more 
efficient delivery of therapeutic cargo.6 Despite the success of these advances, there 
remain some inherent concerns. One primary obstacle to the success of encapsulation 
strategies is the inability to directly characterize the final drug-loaded carrier, leading to 
quantification of associated drug molecules by means of indirect methods. Additionally, 
these strategies employ noncovalent interactions as the primary mechanism for drug 
loading. Given that said interactions are governed by dynamic equilibrium, a ratio of 
bound vs. unbound drug should exist, leading to poor loading efficiencies as well as 
premature drug dissociation. Further, storage of loaded delivery systems is virtually 
impossible as encapsulated material will begin to leach out instantaneously. Equally 
problematic are the difficulties associated with controlling the release of encapsulated 
materials. Ideally, drug molecules will remain securely bound within the core of the 
delivery system until their rapid discharge is triggered by some biological agent unique to 
the target environment. However, many systems rely on exogenous triggers such as near 
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IR irradiation and photoinduced disruption by UV light, while others simply rely on the 
passive diffusion of drug from the carrier to the target.7"10 While improvements in drug 
delivery are being developed at an increasing rate,11"15 it remains the ultimate goal of this 
field to create delivery systems possessing high loading efficiencies with minimal 
premature drug dissociation while effecting release through endogenous biological 
pathways. 
1.2. Emergence of Nanomedicine: Applications of Gold 
The application of gold in medicine is not a recent concept. In fact, it is believed 
that gold has been used to treat various ailments throughout recorded history. Being 
highly biocompatible, gold enjoys widespread use in many contemporary medical 
applications, the most common of which being the treatment of rheumatoid arthritis. ' 
Associated with having an antimicrobial quality, gold is also increasingly utilized in 
implant technology as it imparts a level of resistance to bacterial infection.18 While 
primarily used as an anti-inflammatory substance, recent advances in the synthesis of 
various gold based nanostructures have generated renewed interest in their alternative 
uses in medicine.19"22 Attracting a large portion of this interest is the photo induced 
ablation of tumors based on the near infrared irradiation of gold nanorods and 
nanoshells.23"28 Arising from unique physical dimensions, these structures, unlike normal 
tissue, are capable of absorbing light in the near IR region and converting it to heat, 
which has been exploited in the thermal destruction of cancer cells. Interestingly, near IR 
light can be focused on a small region (i.e. tumor site), allowing for a more directed 
approach to treatment resulting in an improved side effect profile. 
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In addition to the unique physical properties of gold nanostructures, the ability to 
functionalize their surface with thiol-terminated ligands has been the primary driving 
force behind the growing interest in bionanomaterials. Consequently, conjugation of 
targeting moieties to gold nanoparticles increases their interaction with specific sites in 
the body, which has lead to advances in biomedical imaging as well as the early detection 
of disease.29"35 Additionally, the grafting of thiol-terminated molecules has been utilized 
towards developing nanoparticle-based delivery vectors focused on the intracellular 
delivery of therapeutic agents.36'37 Further expressing their potential as delivery vehicles, 
AuNPs are capable of exploiting the enhanced permeation and retention effect (EPR) 
associated with tumor tissue, thereby having the ability to preferentially accumulate 
inside of tumors upon introduction into blood stream circulation.38 Due to this passive 
targeting capability coupled with the ability to covalently bind biologically active 
molecules to their surface, gold nanoparticles posses the potential to greatly improve the 
delivery of anticancer agents to solid tumors, thereby reducing their systemic toxicity. 
1.3. Paclitaxel: The Holy Grail of Hydrophobic Drug Delivery 
Isolated from the bark of the Pacific Yew tree Taxus brevifolia, the highly potent 
anticancer agent paclitaxel (PTX) has garnered much attention due to its ability to 
efficiently inhibit cell growth at extremely low concentrations.39' 40 Resulting from its 
remarkable activity, paclitaxel is currently used in the treatment of various forms of 
cancer including, but not limited to breast, ovarian and lung cancer. The drug's action is 
based on the ability of paclitaxel to bind to P-tubulin monomers of microtubules found in 
the cytosol of cells as first illustrated by Horwitz and coworkers in 1979.41 The presence 
of paclitaxel is known to cause the hyperstabilization of these microtubules, leading to 
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interference with their normal function hence, a cessation of cellular division. Further 
increasing the attractiveness of this compound, paclitaxel exhibits the ability to encourage 
apoptosis giving rise to a secondary mode of action for the drug. 
While one of the most active cancer fighting agents in clinical use today, 
paclitaxel is not without limitations. Lending to the inability to differentiate between 
cancerous and healthy cells, paclitaxel is associated with a very poor side effect profile. 
Primarily, treatment results in the destruction of the immune system as well as severe 
problems with the digestive tract, causing paclitaxel to be equally devastating to the 
disease it is intended to cure. Additional problems arise from the highly hydrophobic 
nature of the drug. Paclitaxel is notoriously water insoluble and must first be dissolved in 
a mixture of cremophor EL and ethanol prior to aqueous administration. Unfortunately, 
cremophor EL has been linked to its own deleterious effects as it causes hypersensitivity 
resulting in the required administration of steroids and antihistamines prior to paclitaxel 
treatment.42' 43 Given the drug's potent anticancer capabilities as well as the problems 
associated with nonselectivity and aqueous insolubility, it is not surprising that a vast 
majority of delivery strategies are focused on improving the administration of paclitaxel 
via encapsulation in macroscopic assemblies. 
1.4. Specific Goal of this Study 
The specific aim of this thesis is the development of a gold nanoparticle (AuNP) 
based delivery system as an alternative to traditional encapsulation methods. It is 
hypothesized that having biologically active molecules comprise the exterior of the 
conjugate will exhibit many significant advantages relative to their entrapment in the 
interior of self assembled capsules. Primarily, the covalent binding of paclitaxel to the 
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surface of AuNPs results in a much stronger drug-carrier interaction, leading to increased 
structural stability for the hybrid system while decreasing the probability of premature 
drug dissociation. Additionally, we have previously demonstrated that hybrid systems 
containing an organic shell are suitable for structural characterization using traditional 
analytical techniques such as !H NMR.44' 45 Said analysis should prove vital in the 
manufacturing of a well-defined carrier system as this route will allow for direct 
characterization of the final chemical structure and therefore, and increased ability to 
measure biological activity. Similar to reported encapsulation methods, the highly 
modifiable surface of AuNPs allows for the subsequent addition of targeting molecules 
such as peptides and antibodies, which can increase carrier interactions with specific sites 
in the body. In addition to potential targeting, solubulizing agents such as polyethylene 
glycol (PEG) can be attached to the gold surface, increasing the water solubility of the 
carrier, thus negating the necessity of using cremophor EL for the aqueous delivery of 
paclitaxel. Furthermore, the ability to incorporate PEG chains into the carrier structure 
may also result in a more favorable biological distribution profile as PEG is known to 
greatly increase circulation times in the body via RES avoidance. 
While there are many potential advantages to the covalent binding of paclitaxel to 
AuNPs, influencing the subsequent release in a controllable manner remains problematic. 
Able to impart structural stability into the system, a covalent approach also increases the 
complexity associated with the discharge of bound drug, causing this method to be less 
attractive for the same reason that it is favorable. In fact, determining a mechanism for 
the efficient and quantitative dissociation of bound PTX from the gold surface is a 
primary obstacle addressed in a significant portion of the following chapters. Herein we 
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wish to report on efforts towards the design of AuNP carriers utilizing a covalent binding 
strategy capable of the quantitative intracellular delivery of the potent chemotherapeutic 
drug. 
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Chapter 2: Synthetic Blueprint for the Production of Weil-Defined 
Paclitaxel- Functionalized Gold Nanoparticles 
2.1. Introduction 
Attractive for their size, stability, and biocompatibility, gold nanoparticles (NPs) 
continue to gain interest due to their potential to enhance a number of biomedical 
applications.1"14 More importantly, the ability to functionalize the surface of gold with 
organic molecules allows for the preparation of nanoparticles which can specifically 
interact with any physiological system.15"23 Despite numerous examples detailing the 
coupling of biologically active compounds with AuNPs, observing and proving the 
presence of covalently bound molecules has been mainly limited to qualitative studies. In 
many cases only indirect methods can be used as an argument for successful covalent 
attachment because the power of solution characterization techniques (NMR, SEC, and 
LS) is often negated by low solubility and structural inhomogeneities of hybrid organic-
inorganic structures. As a consequence, there exist very few reports on the preparation of 
organic-inorganic systems containing a specific number of drug molecules. In our 
previous work,24 we have shown that polymer-functionalized metallic nanoparticles 
featuring a 2 nm gold core are, in fact, suitable for traditional characterization methods in 
solution and therefore, present an attractive opportunity for manufacturing drug delivery 
vehicles with tunable properties. In this work we describe the synthesis of a paclitaxel-
gold nanoparticle hybrid structures in which the covalent attachment of paclitaxel 
molecules to the surface of 2 nm gold nanocrystals is observed using standard analytical 
techniques. The synthetic strategy described here yields a hybrid structure with 
11 
extremely high content of organic shell (67 wt. %), low polydispersity index (1.02), and a 
well-defined number of drug molecules (70±2) per metallic particle. This well-defined 
chemical structure of drug-functionalized nanoparticles allows one to more accurately 
define their efficacy and therapeutic utility. 
2.2. Synthesis of Paclitaxel-Functionalized Gold Nanoparticles 
Preparation of the paclitaxel-AuNP conjugate begins with the synthesis of a linear 
analog featuring a hydrophilic, carboxyl-terminated linker (hexaethylene glycol) 
anchored at the C-7 position of paclitaxel, which can be directly coupled to 4-
mercaptophenol-functionalized 2 nm Au particles. Selection of the C-7 hydroxyl group 
as the point of attachment was motivated by the structure-activity relationships reported 
for paclitaxel,25"28 which show that chemical modification of this site does not cause any 
significant change in paclitaxel's ability to arrest cell division processes in cancer cells. 
This is in contrast to C-2' OH group, modification of which results in either drastic 
reduction or complete disappearance of biological activity. While reports on analogous 
paclitaxel compounds modified at the C-2' OH exist,29'30 these examples rely on 
enzymatic processes capable of unmasking this hydroxyl group in vivo. Furthermore, 
modifying the C-7 position is less likely to alter the biologically active T-shaped 
conformation, as defined by Kingston et al.31 Incentive for the inclusion of hexaethylene 
glycol (HEG) into the structure of this linker is twofold in that (1) HEG increases the 
water solubility of the product, which can be further increased by introducing longer 
polyethylene glycol (PEG) linkers, and (2) the presence of multiple ethylene glycol units 
has been shown to minimize opsonization and RES clearance, hence increasing 
circulation time in the body.32"35 
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Selective protection of the ester-activated C-2' OH group of paclitaxel with tert-
butyldimethylsilyl (TBS) chloride was carried out under standard conditions to afford 2 
with a 97 % isolated yield. This approach gives exclusive access to the hydroxyl group 
located at the C-7 position because the C-l tertiary hydroxyl is sterically hindered and 
remains unreactive under these mild conditions (Scheme 1). 1,3-Diisopropyl 
carbodiimide (DIPC) and 4-(A^-dimethylamino)pyridinium-4-toluenesulfonate (DPTS) 
HO OH 
HO OTIPS 
—*~ HO 
DIPC, DPTS 
CH2CI2, rt, 59% 
v-W-
AcO O OH 
HO OBz < 
TBSCI 
Imidazole 
DMF 
HO OTIPS 
DIPC, DPTS 
CH2CI2, rt, 80% 
1 R=H 
-»- 2R=TBS, 97% 
HO O B z O A c 
HOAc, THF 
50°C,12 h 
3 R=TIPS 
4 R=H,93% 
OR 
HO 
O O 
OTIPS 
DIPC, DPTS 
CH2CI2, rt, 78% 
O O 
OTBS H O O B z 
HOAc, THF 
50°C,12 h 
5 R=TIPS 
-*• 6 R=H, 91% 
OR 
Scheme 1. Synthesis of a paclitaxel analog featuring a hexaethylene glycol linker at the C-7 
position. 
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have been shown to effect esterification in high yields, and represent the standard 
coupling agents described in this sequence.37'38 Introduction of a carboxylic acid 
functionality at the C-7 position was achieved upon the coupling of 2 with glutaric acid 
monotriisopropylsilyl (TIPS) ester followed by selective cleavage of the TIPS group 
using acetic acid in THF at slightly elevated temperatures (50° C). Importantly, under 
these conditions C-2' OTBS remains intact as confirmed by 'H NMR analysis. Acetic 
acid has been shown to minimize the formation of side products when used in the 
synthesis of paclitaxel.39 
In a separate synthesis, the hexaethylene glycol (HEG) portion of the linker was 
prepared by coupling excess HEG (5 mol equiv.) with glutaric acid monotriisopropylsilyl 
ester in the presence of DIPC/DPTS, which was then reacted with compound 4 under the 
same esterification conditions to give the desired product 5 in 78 % isolated yield. 
Again, acetic acid was employed to selectively cleave TIPS group, providing a TBS-
protected paclitaxel analog 6, which features a carboxyl-terminated HEG linker. 
Interestingly, we were able to take advantage of paclitaxel's poor solubility profile as 
several intermediates (2, 4, and 6) are not soluble in non-polar solvents, allowing for the 
clean precipitation of the product from hexane as a common protocol for purification. 
Standard conditions were employed for the coupling of TBS-protected paclitaxel 
derivative 6 and 4-mercaptophenol-functionalized Au nanoparticles (Scheme 2), which 
were prepared using a modified procedure introduced by Brust and coworkers. 
However, dropwise addition of 30 % DMF to methylene chloride suspension of AuNPs is 
required to bring the hydroxyl-terminated particles into solution as they are not readily 
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soluble in non-polar solvents. Progress of this reaction is easily monitored as the nature 
of 7 renders the system compatible with size exclusion chromatography (SEC). SEC 
traces taken after two hours show near complete consumption of 6 and the presence of a 
high molar mass peak with a very low polydispersity index (PDI=1.02) corresponding to 
TBS-protected paclitaxel-functionalized gold nanoparticles 7 (Figure 1). This 
remarkably low value of PDI is indicative of a nearly monodisperse size of hybrid 
nanoparticles in solution as well as a uniform distribution of paclitaxel molecules along 
their surfaces. 
/, !^Mi(V 
Scheme 2. Covalent coupling of paclitaxel to 4-mercaptophenol-modified 2 nm gold 
nanoparticles. 
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The molar mass of hybrid nanoparticles 7 measured by SEC relative to 
polystyrene standards is highly underestimated as the molecular weight of 2 nm gold 
clusters alone is at least 53,000 Daltons (-270 Au atoms). In addition, SEC analysis is 
known to underestimate the molecular weight of branched structures, i.e. dendrimers and 
star-shaped polymers, when the hydrodynamic radii of linear standards are used for 
calibration.41 Chromatograms taken after four and eight hours reveal similar ratios of 
product to starting material, suggesting that the maximum possible amount of 6 is 
coupled to AuNPs within the first two hours. Purification of 
^1 
PDI = 1.02 
MSEC = 10,500 
•*""£"" "ib " is Yo is s¥" is 
Minutes 
Figure 1. Size exclusion chromatography traces showing the coupling of compound 6 to the 
surface of AuNPs (bottom), and the isolated product 7 after purification (top). 
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the product 7 is equally simplified as its much larger size can be exploited by centrifugal 
ultrafiltration. DMF solutions of the reaction mixture were placed on regenerated 
cellulose membranes with MWCO 30 kDa and centrifuged at 3,750 rpm. Only three 45-
minute rounds of centrifugation were necessary for the complete removal of all starting 
materials as determined by SEC (Figure 1, top). Lastly, the synthesis of the paclitaxel-
AuNP conjugate 8 was complete upon liberation of the C-2' OH groups of paclitaxel 
moieties using HF in pyridine (70:30 v/v, respectively), followed by precipitation from 
hexane affording 8 as a grey-brown powder. 
2.3. Structural Characterization of Paclitaxel-AuNP Conjugate 
Upon purification, the successful coupling of paclitaxel to Au nanoparticles was 
confirmed by *H NMR. Figure 2 details the proton spectra for paclitaxel-HEG analog 6 
(top) and the final product 8 (bottom). The overall appearance, position, and the 
integration values of all major signals are very similar. In both cases, the integration ratio 
of paclitaxel aromatic protons, for example C-23, C-27 doublet at 8.11 ppm, to HEG non-
terminal aliphatic protons at 3.65 ppm remains the same (2H vs. 24H). In addition, the 
location of a triplet corresponding to the C-7 proton in both products 6 and 8 is at 5.6 
ppm (Figure 2), which is very different from that of free paclitaxel where the C-7 proton 
appears at 4.4 ppm. Because this triplet integrates exactly as 1H, one can conclude that 
all paclitaxel moieties in product 8 are attached to the glutaric acid-HEG linker. The 
linker, in turn, must be connected to gold nanoparticles because SEC analysis of 8 
demonstrated complete absence of precursor 6 or any other low molar mass species (Fig. 
1, top). On the other hand, there are distinct differences in the two spectra presented in 
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Figure 2. 'H NMR spectra of paclitaxel analog 6 (top) and the isolated hybrid structure 8 
(bottom). 
Figure 2. Nearly all signals from the final product 8 are broader compared to those of 6, 
which is indicative of the decreased rotational mobility of paclitaxel moieties covalently 
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attached to the surface of gold nanocrystals. Most affected by this phenomenon are those 
signals associated with HEG (4H at 4.2 ppm and 22H at 3.65 ppm) and glutaric acid (1.7-
2.4 ppm), lending to their closer proximity to the gold surface. 
It is important to emphasize, however, that the presence of the highly flexible and 
relatively long HEG linker is crucial for the NMR characterization of paclitaxel-
functionalized nanoparticles. Our control experiment showed that nearly all resonances 
become exceedingly broad and unrecognizable if paclitaxel is directly coupled to the 
surface of AuNPs (without the HEG linker). Another important feature of the NMR 
spectrum collected from 8 is a very broad signal in the range between 7.2 and 6.7 ppm. 
This is due to the presence of 4-mercaptophenol ligands, which connect paclitaxel-HEG 
chains to the surface of AuNPs. The broad signal appears only after the attachment, and 
it is not present in the starting material 6. Finally, several fine changes in the spectra 
prove complete deprotection of the C2'-OH group. First, the signals of TBS methyl 
groups (0 and -0.3 ppm) and f-butyl group (0.8 ppm) are not observed in the spectrum of 
the final product 8. Second, the resonances of protons attached to C-2' and C-3' undergo 
slight shifts downfield from 4.65 to 4.82 ppm, and from 5.7 to 5.8 ppm, respectively 
(Figure 2). Additionally, a small upfield shift of the C-13 proton takes place upon the 
deprotection, and the signal is no longer overlapped with that of the C-10 proton as in 
precursor 6. This slight separation of C-10 and C-13 signals was only observed in the 
final product 8 and in the unprotected paclitaxel, whereas the NMR spectra of all TBS-
protected intermediates 2 through 7 showed a complete overlap of these particular peaks. 
In order to confirm that the soluble product 8 with a high molecular weight (SEC) 
and the NMR spectrum similar to precursor 6 is indeed a hybrid organic-inorganic 
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structure, we performed several TEM experiments. First, we imaged the starting 2 mm 
gold nanoparticles coated with 4-mercaptophenol. Figure 3a shows a low magnification 
T. image of AuNPs deposited from a THF solution onto a carbon-coated grid. The 
average size of the particles is close to 2 nm, although structures as small as 0.7 nm and 
as big as 4.3 nm can be found in the image. The inter-particle distance also varies within 
Figure 3. TEM and HRTEM images of 4-mercaptophenol-coated Au NPs (a, c), and paclitaxel-
functionalized Au NPs (b, d). 
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a relatively large range (0.5 to 3 nm), but the average value is close to 1 nm, which is in 
good agreement with earlier reports.42 Importantly, TEM imaging of the final product 8 
reveals the presence of spherical particles with a very similar average size of ~2 nm 
(Figure 3b), which implies that during the coupling of compound 6 and the deprotection 
of nanoparticles 7, Oswald ripening of metallic cores did not occur. However, the inter-
particle distance is substantially increased (-2.5 nm), indicating the presence of a much 
larger organic shell. This distance is approximately twice the size of a paclitaxel 
molecule, but it is shorter than the length of compound 6 in its fully extended 
conformation (4.6 nm). High flexibility and small cross-sectional area of HEG chains 
may explain this difference. It is reasonable to expect that drying would cause HEG 
linkers to collapse near the surface of the gold core. In addition, the interdigitation of 
ligands from adjacent nanocrystals may take place in accord with the observations 
reported for alkanethiolate gold clusters.68"71 
The conventional bright-field TEM, however, does not prove that the dark 
spherical objects shown in Figure 2a and 2b are indeed gold nanocrystals. For that 
purpose we employed high resolution TEM imaging of both mercaptophenol- and 
paclitaxel-functionalized nanoparticles 8 (Figure 3 c,d). The majority of particles exhibit 
the characteristic lattice fringes, which represent the individual atomic layers. The d-
spacing between the fringes is either 2.04 or 2.35 A, which allows one to identify them as 
{200} and {111} crystallographic planes of fee Au, and offers definitive proof that these 
structures are crystalline. Most of the particles are single crystals, and only occasional 
twinning of particles is observed. Importantly, HRTEM clearly demonstrates that the 
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average size of particles and their degree of crystallinity have not been altered during the 
multi-step synthesis and several ultrafiltration steps en route to the final product 8. 
Figure 3d also shows that metallic cores of hybrid structures 8 have near-spherical 
shapes, which simplifies the estimation of the number of organic molecules attached and 
their grafting density, as discussed below. 
2.4. Quantification of Bound Paclitaxel 
The number of paclitaxel molecules attached to each Au particle was first 
determined qualitatively from the weight gain observed upon the isolation of paclitaxel-
functionalized nanoparticles 8. Based on the mass of product (24 mg) formed from the 
starting AuNPs (9.5 mg), one can estimate that the mass increase is approximately 150 % 
by weight, which is due to the covalent attachment of HEG-paclitaxel moieties. It has 
been previously reported that 2 nm gold clusters contain -270 atoms72 (MAu =53,000 Da) 
-7-5 
and that the number of thiol ligands protecting their surface is approximately 90. The 
molecular weight of mercaptophenol-coated particles is then 64,250 Da (MAu + 
90 MC6H5os), and the increase of 150 % corresponds to -96,400 Da. Given the molecular 
weight of 6 (1,342 g/mol, without TBS), there are on average 96,400/1,342 = 72 
paclitaxel molecules per one AuNP. However, this estimation assumes a quantitative 
conversion of starting Au nanoparticles to product 8. 
In order to corroborate the calculated number of paclitaxel molecules, 8 was 
subjected to thermogravimetric (TGA) analysis which allows for direct measurement of 
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Figure 4. TGA data measuring the loss of organic material corresponding to 4-mercaptophenol-
coated AuNPs (red) and hybrid structure 8 (blue). 
the weight content of organic shell. As a control, 4-mercaptophenol-functionalized 
AuNPs were first analyzed in order to measure the amount of organic material 
(mercaptophenol ligands) present before the coupling of 6. The result of this experiment 
reveals that thiol ligands account for approximately 23.1 % of the mass of stock AuNPs 
(Figure 4, top). Coupled with the molar mass of mercaptophenol (125 g/mol), each Au 
particle was found to contain 126 functional sites. Using this same procedure, the 
composition of 8 was determined to be 67.1 % organic and 32.9 % metallic Au. Since 
the molecular weight of the gold core is 53 kDa, the total molecular weight of organic 
shell is then 108 kDa. Assuming that the number of mercaptophenol ligands remained 
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constant, the molecular weight of HEG-paclitaxel moieties is 92.3 kDa (108,000 -
126Mc6H50s), which gives approximately 69 molecules per particle. This remarkable 
agreement between the TGA data and the estimation based on the mass gain upon 
coupling reaction, indicate the reliability and high accuracy of both methods. These 
results also reveal the high efficiency of the synthetic strategy used for the preparation of 
hybrid structures described here. To the best of our knowledge, the organic content (67.1 
wt. %) in nanoparticles 8 is the highest value reported for any hybrid structures to date. It 
significantly exceeds the records reported for polymer-functionalized AuNPs with high 
grafting density (56.5 %).74 Therefore, our approach allows for the preparation of core-
shell nanostructures, which are well-defined in terms of their size, the content of organic 
layer, and the number of molecules grafted to the inorganic core. Most importantly, one 
can use this strategy to prepare hybrid systems with a high drug loading capacity. 
2.5. Measurement of Growth Inhibition for Paclitaxel-AuNP Conjugate in vitro 
Having designed a unique synthetic strategy towards the construction of a 
paclitaxel-AuNP delivery system possessing a well-defined structure as well as a 
quantifiable amount of bound drug, experiments were performed to measure the in vitro 
ability of 8 to inhibit cell growth compared to free paclitaxel. Initial experiments were 
performed by our collaborators at M.D. Anderson in the laboratories of Jeff Meyers. 
Briefly, two cell lines (OSC-19 Luciferase and DM14) were treated with a range of 
concentrations of 8 and the parent drug, while measuring cell survival relative to 
untreated controls 72 hours post treatment following the MTT procedure. Results from 
these experiments are shown in Figures 5 and 6. 
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Growth Inhibition of OSC-19 Luciferase Cells 
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Figure 5. Growth inhibition of OSC-19 Luciferase cells observed for PTX-AuNP 8 and free 
paclitaxel. 
Initial data reveal a drastic reduction in cellular toxicity in both cell lines upon the 
attachment of 6 to the surface of AuNPs. These results are somewhat surprising as 
modification of the C-7 hydroxyl has been shown in the literature to have a minimal 
affect on the cytotoxic profile of PTX. Additionally, care was taken to ensure that the 
more crucial C-2' hydroxyl remains uncovered on the exterior of the organic shell, 
providing access to the binding pocket of p-tubulin. This observed reduction in 
biological activity may be explained by the emergence of steric interactions at the 
densely packed gold surface, which prevent such desired 
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Figure 6. Growth inhibition of DM14 cells observed for PTX-AuNP 8 and free paclitaxel. 
drug-target interactions. In order to test this hypothesis, intermediates 4 and 6 were also 
analyzed for antiproliferative ability prior to their attachment to AuNPs (Figure 7). 
Unfortunately, even slight structural modification at the C-7 position results in a 
significant reduction in activity as observed for PTX-7 glutarate 4. Inexplicable is the 
improved activity exhibited by the incorporation of HEG into the linker structure 
(intermediate 6). If a steric argument is to be employed, then further modification of 4 
would result in an even greater loss of toxicity. Additionally, the presence of repeating 
ethylene glycol units (i.e. PEG) is a frequently utilized prodrug strategy aimed at 
reducing drug interactions with endogenous biological processes. Interestingly, being 
that IC50 values for 4 and 6 (>100 nM) are two orders of magnitude higher than that of 
free paclitaxel (approximately 1 nM), it is concluded that the virtual complete loss of 
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activity observed for AuNP 8 does not result from steric hindrance nor is it attributed to 
the presence of the gold core. However, these data strongly suggest that attachment of 
the chemical linker at the C-7 hydroxyl should be abandoned. 
Growth Inhibition of MDA 1986 Cells 
paclitaxel 
PTX-7-Glut 4 
PTX-7-HEG 6 
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Figure 7. Growth inhibition of intermediate compounds 4 and 6 on MDA 1986 cell line 
compared to free paclitaxel. 
2.6. Conclusion 
A novel approach towards the preparation of a well-defined drug-gold 
nanoparticle system has been described. The resulting hybrid structure is unique in that 
the small ratio of gold core to organic shell allows for both solution and solid-state 
characterization based on powerful analytical techniques. Such analysis reveals a system 
containing a well-defined number of paclitaxel molecules with near uniform composition, 
as evidenced by SEC, NMR, TEM, and TGA experiments. Perhaps most importantly, 
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this approach allows for a more accurate measurement of biological activity as a result of 
the increased ability to quantify the amount of drug present. 
While linking paclitaxel to the surface of AuNPs through the C-7 hydroxyl was 
motivated by rational design, initial cell culture tests reveal even slight modification of 
this site as detrimental to the parent drug's ability to influence cell cycle arrest. Initially 
attractive for their reported stability to hydrolysis, C-7 esters described in this chapter are 
structurally significant enough to alter paclitaxel-P-tublin binding, resulting in the 
observed loss of biological activity. As a result, alternative methods for the covalent 
linking of paclitaxel were investigated and progress towards the ultimate goal of an active 
AuNP-paclitaxel conjugate is discussed in subsequent chapters. 
2.7. Experimental Methods and Materials 
Unless otherwise stated, all starting materials were obtained from commercial 
suppliers and used without further purification. !H NMR were recorded in CDCI3 using a 
Bruker 400 MHz spectrometer. Size Exclusion Chromatography (SEC) analysis was 
performed on a Waters Breeze 1515 series liquid chromatograph equipped with a dual X 
absorbance detector (Waters 2487), automatic injector, and three styrogel columns (HR1, 
HR3, HR4) using linear polystyrene standards for the calibration curve and 
tetrahydrofuran (THF) as the mobile phase. Thermogravimetric analysis was performed 
on a TA Instruments TGA Q50. 3.0-6.0 mg samples were placed in platinum sample 
pans and heated under argon atmosphere at a rate of 10 °C/min to 100 °C and held for 30 
minutes to completely remove residual solvent. Samples were then heated to 700 °C at a 
rate of 10 °C/min. TEM and HRTEM imaging was performed on a JEOL 21 OOF 
transmission electron microscope operating at 200 kV accelerating voltage. Samples 
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were drop cast from dilute solutions of 10 % THF in CH2CI2 onto carbon-coated TEM 
grids and allowed to dry in open air. Centrifugal filters (2 mL capacity) Ultrafree®-CL 
containing regenerated cellulose membranes with a molecular weight cut-off of 30,000 
g/mol were purchased from Fisher Scientific Inc. 4-(N, N-dimethylamino)-pyridinium-4-
toluenesulfonate (DPTS) was prepared by mixing saturated THF solutions of N,N-
dimethylaminopyridine (DMAP) (1 equiv) and p-toluenesulfonic acid monohydrate (1 
equiv) at room temperature. The precipitate was filtered, washed several times with 
THF, and dried under vacuum. 
2.7.1. Synthetic Methods 
Glutaric acid mono-triisopropylsilyl ester. 3.2 g (16.6 mmol) of triisopropylsilyl 
chloride (TIPSC1) were introduced dropwise into a solution of 2.0 g (15.1 mmol) glutaric 
acid in 25 mL DMF. The reaction vessel was then equipped with a rubber septum and 
under rigorous agitation, 1.45 g (16.5 mmol) morpholine were slowly injected via 
syringe. After 5 min the reaction was stopped by diluting the mixture 5 fold with 
dichloromethane, removing DMF and morpholine by washing the organic solution 4 
times with DI water followed by 1 extraction using an aqueous solution of 3 % citric 
acid. The solvent was then reduced on a rotary evaporator at 40 C and the crude product 
purified by column chromatography using 5 % THF/CH2CI2 as an eluent (Rf=0.60). The 
result was a colorless oil with a typical yield of 1.70 g (39 %). 'HNMR (CDC13) 5 1.06 
(d, 18H)a, 1.30 (m, 3H)b, 1.95 (m, 2H), 2.44 (t, 4H). 
Glutaric acid triisopropylsilyl ester hexaethylene glycol ester. 0.5 g (1.7 mmol) of 
mono TIPS-glutaric acid, 2.5 g (8.85 mmol) hexaethylene glycol, and 0.8 g (2.7 mmol) 
DPTS were dissolved in 30 mL of dichloromethane. After all components were in 
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solution, 1 mL (7.7 mmol) of DIPC were added. Complete consumption of starting 
TIPS-glutaric acid was observed by GPC after 2 hours. The reaction was stopped by 
diluting with dichloromethane and removing DPTS via 5 extractions with DI water. The 
organic fraction was reduced and the product isolated by column chromatography eluting 
with 20 % THF/CH2C12 (Rf=0.40). Yield 0.568 g (59 %). 'HNMR (CDC13) 5 1.06 (d, 
18H)a, 1.27 (m, 3H)b, 1.93 (m, 2H), 2.40 (t, 4H), 3.67 (m, 22H), 4.21 (m, 2H). 
2'-OTBS-paclitaxel (2). A stock silylating solution was prepared by dissolving 0.57 g 
(3.8 mmol) tert-butyldimethylsilyl chloride (TBSC1) and 0.52 g (7.6 mmol) imidazole in 
1.0 mL of dry DMF. Please note that the final volume of the silylating solution was more 
than 1.0 mL. 0.50 mL of this stock solution was then used to dissolve 100 mg (0.12 
mmol) of paclitaxel. The reaction was monitored by TLC using 1:1 (v/v) hexane:EtOAc 
as an eluent (product Rf=0.40). Complete disappearance of starting Taxol (Rf=0.10) was 
observed after 30 min and the reaction was quenched by diluting with dichloromethane 
and extracting DMF and imidazole with DI water. The remaining dichloromethane 
solution was concentrated and precipitation from hexane provided 110 mg of the final 
product as a white powder. Yield 97 %. 'H NMR (CDCI3) 5 -0.27 (s, 3H)C, -0.03 (s, 
3H)C, 0.81 (s, 9H)C, 1.14 (s, 3H), 1.25 (s, 3H), 1.69 (s, 3H), 1.91-1.93 (broad, 4H), 2.15 
(m, 1H), 2.23 (s, 3H), 2.45 (m, 1H), 2.57-2.58 (broad, 4H), 3.83 (d, 1H), 4.24 (d, 1H), 
4.32 (d, 1H), 4.40 (m, 1H), 4.67 (s, 1H), 5.00 (d, 1H), 5.69 (d, 1H), 5.72 (m, 1H), 6.30 
(broad, 2H), 7.09 (d, 1H), 7.33 (m, 3H), 7.41 (m, 4H), 7.50 (m, 3H), 7.60 (m, 1H), 7.74 
(d,2H), 8.13 (d,2H). 
Compound 3. 160 mg (0.17 mmol) of compound 2, 75 mg (0.26 mmol) mono TIPS-
glutaric acid, and 100 mg (0.33 mmol) DPTS were placed in a small vial and dissolved in 
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2.0 mL dichloromethane. Upon stirring for 5 min, 100 mg (0.79 mmol) DIPC were 
added dropwise to initiate coupling. After 4 hours, the absence of starting 2 was 
observed by GPC. The reaction was stopped via 5 fold dilution of the reaction mixture 
with dichloromethane and 4 water extractions to remove DPTS. The crude product was 
purified by column chromatography using 2:1 (v/v) hexane:EtOAc as an eluent 
(Rf=0.60). The yield for this reaction was 163 mg (80 %). [H NMR (CDC13) 5 -0.29 (s, 
3H)C, -0.01 (s, 3H)C, 0.81 (s, 9H)C, 1.07 (broad, 18H)a, 1.17 (s, 3H)b, 1.22 (m, 3H), 1.82-
1.95 (m, 6H), 1.99 (s, 3H), 2.15-2.20 (broad, 4H), 2.35-2.45 (m, 5H), 2.58 (broad , 4H), 
3.95 (d, 1H), 4.23 (d,lH), 4.34 (d, 1H), 4.68 (s, 1H), 4.95 (d, 1H), 5.65 (t, 1H), 5.72 (m, 
2H), 6.28 (broad, 2H), 7.09 (d, 1H), 7.33 (m, 3H), 7.43 (m, 4H), 7.51 (m, 3H), 7.62 (m, 
1H), 7.75 (d, 2H), 8.13 (d,2H). 
Compound 4. 5.6 mL of glacial acetic acid were added to a solution containing 150 mg 
(0.12 mmol) of 3 in 2.0 mL THF. After the dropwise addition of 0.40 mL H2O, the 
reaction mixture was heated to 50°C. The reaction was monitored by TLC eluting with 
2:1 (v/v) hexane:EtOAc. After 12 hours, the complete conversion of carboxyl protected 
compound (Rf=0.60) to the free carboxyl product (Rf=0.10) was observed. The reaction 
mixture was diluted with dichloromethane and washed 5 times with DI water. The 
organic fraction was reduced on a rotary evaporator at 40°C and precipitation from 
hexane yielded 122 mg (93 %) as a white solid. 'H NMR (CDC13) 5 -0.28 (s, 3H)C, -
0.02 (s, 3H)C, 0.81 (s, 9H)C, 1.22 (m, 3H) 1.82-1.90 (m, 6H), 1.99 (s, 3H), 2.15-2.20 
(broad, 4H), 2.33-2.45 (m, 5H), 2.58 (broad, 4H), 3.95 (d, 1H), 4.23 (d, 1H), 4.34 (d, 
1H), 4.68 (s, 1H), 5.00 (d, 1H), 5.65 (t, 1H), 5.72 (m, 2H), 6.28 (broad, 2H), 7.09 (d, 1H), 
7.33 (m, 3H), 7.43 (m, 4H), 7.51 (m, 3H), 7.62 (m, 1H), 7.75 (d, 2H), 8.13 (d, 2H). 
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Compound 5. 191 mg (0.18 mmol) of 4, 150 mg (0.27 mmol) mono TIPS-glutaric acid-
HEG-OH, and 70 mg (0.23 mmol) DPTS were dissolved in 2.0 mL dichloromethane. 
100 mg (0.79 mmol) DIPC was added dropwise after 5 min. The reaction was complete 
after 4 hours as determined by GPC, and removal of DPTS was achieved via 4 DI water 
extractions. The product was purified by column chromatography using 1:3 (v/v) 
hexane:EtOAc as an eluent (Rf=0.65). 223 mg (78 % yield) of product was obtained as a 
colorless oil. 'H NMR (CDC13) 5 -0.30 (s, 3H)C, -0.02 (s, 3H)C, 0.80 (s, 9H)C, 1.08 (broad, 
18H)a, 1.16 (m, 3H)b, 1.21 (m, 3H), 1.82-1.98 (m, 9H), 2.15-2.20 (broad, 4H), 2.33-2.45 
(m, 5H), 2.57 (broad, 4H), 3.67 (m, 22H), 3.85 (m, 2H), 3.95 (d, 1H), 4.23 (broad, 8H), 
4.34 (d, 1H), 4.67 (s, 1H), 4.95 (d, 1H), 5.65 (t, 1H), 5.71 (m, 2H), 6.26 (broad, 2H), 7.09 
(d, 1H), 7.33 (m, 3H), 7.42 (m, 4H), 7.52 (m, 3H), 7.62 (m, 1H), 7.75 (d, 2H), 8.13 (d, 
2H). 
Compound 6. 100 mg (62 |umol) of 5 were dissolved in 2.0 mL THF. While stirring 
vigorously, 5.6 mL glacial acetic acid were added. Lastly, 0.40 mL DI H2O was added 
dropwise and the mixture heated to 50°C. TLC (1:3 mixture of hexane:EtOAc) shows 
the complete conversion of the carboxyl protected compound (Rf=0.65) to the free 
carboxyl product (Rf=0.10) after 12 hours. The reaction was quenched by diluting the 
mixture with dichloromethane and washing several times with DI water. Precipitation 
from hexane gave 82 mg (91 % yield) of isolated product. 'H NMR (CDCI3) 5 -0.29 (s, 
3H)C, -0.02 (s, 3H)C, 0.80 (s, 9H)C, 1.21 (m, 3H), 1.82-1.98 (m, 9H), 2.15 (broad, 4H), 
2.33-2.45 (m, 5H), 2.58 (broad, 4H), 3.66-3.70 (m, 24H), 3.95 (d, 1H), 4.23 (broad, 5H), 
4.35 (d, 1H), 4.95 (d, 1H), 5.65 (t, 1H), 5.75 (m, 2H), 6.26 (broad, 2H), 7.11 (d, 1H), 7.33 
(m, 3H), 7.43 (m, 4H), 7.52 (m, 3H), 7.62 (m, 1H), 7.75 (d, 2H), 8.13 (d, 2H). 
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Au(PTX-2'OTBS)n (7). 9.5 mg of Au(OH)n NPs were taken from a stock solution in /-
Propanol and dried on a rotary evaporator at 45°C. The dried particles were then washed 
3 times with dichloromethane to remove any residual isopropanol. 20 mg (14 umol) 
2'0TBS-Paclitaxel-7-GA-HEG-GA and 12 mg (40 umol) DPTS were dissolved in 2.0 
mL dichloromethane and added to the vessel containing the dried hydroxyl-terminated 
nanoparticles. Please note that the Au(OH)n NPs are not soluble in CH2CI2. Dropwise 
addition of 15 mg (0.12 mmol) DIPC was done after 5 min, followed by addition of 1.0 
mL DMF to bring the Au(OH)n NPs into solution. The reaction was complete after 4 
hours as determined by GPC. DPTS and DMF were removed after several washes with 
DI water and the remaining dichloromethane solution was evaporated on a rotary 
evaporator at 40°C. The crude product was then dissolved in 10 mL DMF and placed in 
a 30 kDa regenerated cellulose membrane filter. The sample was purified by 
ultracentrifugation at 3,750 rpm until only one peak was observed by GPC (high molar 
mass peak). The solution was then concentrated in vacuo and precipitated from hexane, 
resulting in 27 mg of 7 in the form of a grey powder. *H NMR (CDCI3) 5 -0.30 (s, 3H)C, 
-0.02 (s, 3H)C, 0.80 (s, 9H)C, 1.21 (m, 3H), 1.81-1.98 (m, 9H), 2.15 (broad, 5H), 2.30-2.50 
(m, 9H), 2.58 (broad, 6H), 3.64-3.68 (m, 24H), 3.95 (d, 1H), 4.21 (broad, 5H), 4.35 (d, 
1H), 4.95 (d, 1H), 5.65 (t, 1H), 5.75 (m, 2H), 6.26 (broad, 2H), 7.09 (d, 1H), 7.33 (m, 
3H), 7.42 (m, 4H), 7.52 (m, 3H), 7.65 (m, 1H), 7.75 (d, 2H), 8.12 (d, 2H). 
Au(PTX)n (8). 27 mg Au(HEG-Paclitaxel-2'OTBS)n were dissolved in 1.5 mL THF and 
transferred to a small polypropylene vial. While stirring, 0.50 mL of HF in pyridine 
(70:30, respectively) was added (Please note that safe laboratory practices should be 
observed when handling HF). The deprotection was quenched after 4 hours by diluting 
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the reaction mixture with dichloromethane and washing several times with DI water. The 
organic fraction was reduced and washed thrice with hexane, yielding 25 mg of a grey 
powder. !H NMR (CDC13) 5 1.15-1.19 (m, 7H), 1.80-2.00 (m, 14H), 2.15 (s, 4H), 2.20-
2.50 (m, 13H), 2.51-2.70 (broad, 3H), 3.63-3.80 (m, 24H), 3.91 (d, 1H), 4.21-4.28 (broad, 
7H), 4.93 (d, 1H), 5.55 (t, 1H), 5.65 (d, 1H), 5.75 (d, 1H), 6.20 (broad, 2H), 7.15 (broad, 
1H), 7.32-7.62 (m, 12H), 7.75 (d, 2H), 8.10 (d, 2H). 
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2.7.2. NMR Spectra for Intermediate and Final Compounds 
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Figure 8. H NMR spectrum of monotriisopropyl glutarate. 
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Chapter 3: Release of Surface-Bound Paclitaxel via Enzyme-Catalyzed 
Hydrolysis 
3.1. Introduction 
Previously, we developed a paclitaxel-AuNP conjugate, which features the 
covalent grafting of multiple paclitaxel molecules to the surface of gold particles 
measuring 2 nm in diameter. This strategy is unique in that drug molecules are not 
trapped within the core of the carrier, but rather comprise the outer shell of the final 
structure. As a result, traditional analytical techniques can be employed to directly 
confirm the chemical structure and quantify the amount of drug present, allowing for 
increased accuracy in measuring biological efficacy. It is also hypothesized that the 
covalent binding of PTX molecules to the surface of gold nanocrystals will result in a 
much stronger drug-carrier interaction, leading to increased loading efficiencies while 
minimizing premature drug dissociation. However, this covalent strategy further 
complicates the intentional release of PTX as delivery will require the linker to be 
susceptible to in vivo degradation. Herein, we report on work towards identifying 
potential linkers designed to release covalently bound PTX from the surface of AuNPs by 
means of endogenous chemical processes. 
A common motif in prodrug design involves the masking of polar groups such as 
hydroxyls and carboxylic acids through esterification.1"13 There exist several advantages 
to this strategy as esters can impart a more favorable pharmacokinetic profile resulting in 
increased solubility and circulation times, cell permeation, as well as the ability to 
introduce targeting groups such as peptides and antibodies.14"23 Interestingly, ester 
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prodrugs are readily converted back to the parent drug upon enzymatic hydrolysis by 
esterases, which are ubiquitous throughout the body. Given paclitaxel's poor aqueous 
solubility and lack of selectivity, it is no surprise that a great number of PTX prodrugs 
have been studied, many of which are based on this technique. 4" Early attempts at 
improving the solubility of PTX consist of attaching water soluble polymers such as 
polyethylene glycol (PEG) through esterification of the C-2' hydroxyl group.31"33 
Analysis of these analogs shows a marked increase in aqueous solubility of the drug 
while maintaining the ability to be hydrolyzed, releasing the biologically active parent 
compound. More recent studies have exploited this strategy to incorporate targeting 
ligands towards increasing the selectivity of paclitaxel for cancer cells. In fact, some 
examples of PTX-antibody conjugates have been shown to preferentially bind to cell 
surfaces overexpressing complementary binding receptors over receptor deficient cells 
leading to an increase in selective toxicity for the drug.34"37 Considering the established 
utility of paclitaxel-2' esters, we focused our efforts on designing PTX-Au systems 
incorporating a hydrolytically labile ester linkage in hope of demonstrating the controlled 
release and subsequent reactivation of surface bound paclitaxel. 
3.2. Synthesis of Paclitaxel-AuNP Conjugate Featuring a Cleavable C-2' Ester 
Linkage 
The synthetic strategy described here is analogous to that of our previous work in 
that a hexaethylene glycol (HEG) linker is employed to provide both increased aqueous 
stability as well as mobility for the PTX endgroups, which was shown to be crucial for 
detailed structural characterization. Additionally, a flexible linker ensures the ability of 
terminal PTX groups to properly align and interact with endogenous esterases, which is 
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essential for efficient release. However, this strategy diverges from that described 
previously as C-2' esters are more easily hydrolyzed than those at the C-7 position, 
providing a more attractive site for linker attachment. Conversion of the C-2' hydroxyl 
of PTX to a succinate functionality is commonly used in the manufacturing of paclitaxel 
prodrugs and serves here to provide an anchor for which to construct the remaining 
linker.38'39 As this route provides exclusive access to the C-2' site, the necessity for silyl 
protection strategies used previously is negated, thereby reducing the number and 
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Scheme 1. Synthesis of paclitaxel analog featuring a succinate linker at C-2' site. 
difficulty of subsequent synthetic modifications. As reported in the literature, the 
quantitative conversion of starting paclitaxel to its succinate derivative proceeds 
smoothly in pyridine using DMAP as an accelerator (Scheme 1). Carboxyl-terminated 
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intermediate 9 is then coupled with commercially available hexaethylene glycol 
carboxylic acid 7-butyl ester (HEG) under standard DIPC conditions providing 10 in 78% 
yield. This sequence is attractive as it not only provides a faster synthetic route to 
manufacturing the PTX-linker intermediate, but excess HEG can easily be extracted with 
DI water increasing the ease of product isolation. Liberation of the terminal carboxyl 
group is achieved upon treatment of 10 with trifluoroacetic acid (TFA) using 
triethylsilane as a cation scavenger providing 11 in near quantitative yields. Lastly, the 
synthesis of our new system is complete upon the coupling of 11 to the surface of 
mercaptophenol-functionalized AuNPs under standard DIPC/DPTS conditions (Scheme 
2). The relative large size of the hybrid product allows for the removal of unbound 11 
'5 
11 12 
Scheme 2. Covalent grafting of pacltiaxel C-2' analog to the surface of 2 nm AuNPs. 
and excess coupling reagents via centrifugal filtration as described in the synthesis of our 
original system. Briefly, DMF solutions of 12 were placed on regenerated cellulose 
membranes (MWCO of 30 kDa) and repeatedly centrifuged for 40 minutes at 3,700 rpm 
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until low molecular weight impurities were no longer detectable by GPC (generally, three 
to four rounds were required for complete removal). Following purification, the structure 
of 12 was confirmed by H NMR and the amount of bound paclitaxel was quantified by 
TGA as reported previously. Importantly, this alternative approach reduces the total 
number of synthetic steps required to access analogous AuNP-PTX systems (from nine to 
four), allowing increased effort to be delegated to the study of their behavior in biological 
experiments. 
3.3. Measurement of the in vitro Efficacy of Paclitaxel-AuNP Conjugate 12 
Having characterized this new system, cell culture assays were performed to 
measure the in vitro effectiveness of 12 towards inhibiting cancer cell growth. A 
comparative study was carried out by treating MCF-7 breast cancer cells with increasing 
concentrations of Au(PTX) 12 and commercially available paclitaxel following the 
standard MTT protocol. Additionally, intermediate compounds 9 and 11 were evaluated 
to further investigate the effect of structural modification on paclitaxel's cytotoxic 
profile. Data are shown in Figure 1. Initial results reveal that the C-2' succinate 
intermediate has virtually identical activity to starting PTX, providing confirmation that 
efficient hydrolysis of ester linkages at the C-2' position occurs, validating esterification 
as a viable prodrug strategy. However, addition of the HEG moiety appears to cause a 
significant reduction in paclitaxel's ability to arrest cell division as demonstrated by the 
lower growth inhibition observed for 11. This result is not surprising as PEG chains are 
often employed to reduce drug interactions with biological processes in order to improve 
a compound's pharmacokinetic profile.33 Therefore, the decreased activity observed for 
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Growth Inhibition of MCF-7 Breast Carcinoma 
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Figure 1. Growth inhibition of PTX-AuNP 12 and free paclitaxel vs. MCF-7 breast cancer cells. 
Intermediate compounds 9 and 11 are also shown. 
11 can be attributed to the ability of HEG to shield the C-2' succinate group from 
esterases, reducing the rate of hydrolysis and ultimately, efficacy. Most alarming from 
the data presented in Figure 1 is the virtual inability of final product 12 to inhibit cell 
growth. Consistent with literature reports, PTX exhibits an IC50 value in the range of 3-5 
nM, while that observed for the hybrid system is two orders of magnitude higher (500 
nM). This vast difference in activity might be explained by an increase in steric 
interactions at the crowded gold surface rendering the PTX endgroups inaccessible to 
enzymes. However, given the increased IC50 value for 11 (60-70 nM), a more plausible 
hypothesis should be based on the same rationale that the presence of HEG has the ability 
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to shield PTX from hydrolysis. While the ratio of HEG to PTX remains 1:1 in the final 
product, the close proximity of the HEG moieties may give rise to some cooperative 
behavior resulting in increased shielding of esterases thereby drastically reducing the rate 
of PTX release. Although this experiment suggests that hydrolysis of the C-2' position is 
a viable method for delivery, improvements in design are required to increase the 
susceptibility of the linker to esterase degradation while bound to the surface of AuNPs. 
3.4. Development of an Analogous C-2' Linker Towards Increasing the Rate of 
Hydrolysis 
Fortunately, recent reports have demonstrated a simple modification towards 
increasing the rate of hydrolysis for PTX-2' succinate derivatives.40'41 It has been shown 
that replacing the ester oxygen on the terminal carboxyl group of the succinate linker 
with a more nucleophilic atom can influence hydrolysis via anchimeric assistance. The 
proposed mechanism for this process is detailed in Figure 2 and features a five-member 
ring-like intermediate, which increases the efficiency of catalyzed hydrolysis. Simply 
HO O B z O A c 
paclitaxel 
Figure 2. Proposed mechanism towards increasing the rate of hydrolysis based on the idea of 
anchimeric assistance. Substituting a nitrogen at X has been observed to greatly increase the rate 
of PTX release. 
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Scheme 3. Alternate synthesis of paclitaxel C-2' linker featuring an amide bond and the 
subsequent coupling to the surface of 2 nm AuNPs. 
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replacing the terminal ester linkage with an amide is frequently employed for this 
purpose. 
Inclusion of this more labile functionality into the final AuNP structure is easily 
achieved with only slight modification to the above synthetic procedure. Following the 
conversion of starting paclitaxel to the succinate derivative 9, HBTU is employed to 
couple commercially available aminohexaethylene glycol carboxylic acid f-butyl ester, 
forming 13 in 85% yield. Again, isolation of the PTX-linker product is simplified as 
excess aminoHEG is extracted by water prior to purification via column chromatography. 
Removal of the ^-butyl group is complete upon treatment of 13 with a 20% solution of 
TFA in CH2CI2 providing final intermediate 14 in near quantitative yields. Upon 
coupling 14 to the surface of mercaptophenol- functionalized AuNPs, hybrid product 15 
was purified by membrane filtration and subjected to structural analysis as described 
before. 
3.5. In vitro Measurement of Cellular Toxicity of New Analog 
Growth inhibition of MCF-7 breast cancer cells was then measured for 15 
following the aforementioned MTT assay and displayed in Figure 3. Surprisingly, no 
improvement in activity was observed. In fact, the new system appears to exhibit less 
ability to inhibit cancer cell growth than the original gold particle system 12. Given the 
overwhelming literature evidence supporting the efficient hydrolysis of PTX-2' succinate 
derivatives as well as our own results for succinate 9, it is hypothesized that cleavage is 
significantly inhibited upon the coupling of these compounds to the surface of gold 
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nanoparticles. However, it is unclear as to whether this observed trend is a result of the 
shielding effect of HEG or simply steric interactions at the gold surface. 
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Figure 3. Growth inhibition of PTX-AuNP 12 and 15 on MCF-7 breast cancer cells compared to 
free paclitaxel. 
3.6. Release of Surface-Bound Paclitaxel via Enzyme-Catalyzed Hydrolysis 
If the absence of biological activity is directly related to the inability of surface 
bound PTX to be hydrolyzed, then it is imperative to investigate whether release can take 
place under ideal conditions. In order to qualitatively measure the susceptibility of our 
AuNP systems to enzyme catalyzed hydrolysis, compound 15 was exposed to esterase 
activity by incubation in fetal bovine serum (FBS) at 37°C and analyzed by GPC at 
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various time points for free paclitaxel content (Figure 4). Exposure to esterases present 
in serum quickly results in the breakdown of the hybrid analog, releasing bound drug 
from the gold nanoparticles. Consistent with observed hydrolysis half lives of 80 minutes 
PTX Release in FBS 
120 
100 
80 4 
3? 60 
40 
20 -P 
V • free PTX 
• Au(PTX) 15 
• 
10 12 14 16 18 20 22 
Time (h) 
24 
Figure 4. Release profiles for PTX-AuNP 15 showing the appearance of released 
paclitaxel endgroups as well as the simultaneous disappearance of starting 15. 
reported for analogous PTX-2' succinate derivatives,9 the rate of hydrolysis for our 
system is also rapid with approximately 50% of PTX being released within the first 70 
minutes. Equally convincing evidence supporting the efficiency of PTX hydrolysis, is 
the observed degradation of the starting Au(PTX) 15. As the amount of surface-bound 
paclitaxel decreases per particle, the intensity of the signal produced by GPC is 
significantly reduced. Additionally, the shape of the product peak becomes increasingly 
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broad, suggesting a widening range of AuNPs having decreasing amounts of bound drug. 
Coinciding with the appearance of free PTX, the peak area for the PTX-AuNP system 
was found to be 60% of the initial value after only 2 hours. Based on these findings, it is 
concluded that our hybrid PTX-AuNP system is highly susceptible to hydrolysis in the 
presence of enzyme containing serum. Surprisingly, the shielding ability of HEG seems 
to have no deleterious effects on the rate of hydrolysis as previously suggested. 
Additionally, the increase in steric interactions at the Au surface does not appear to 
prohibit esterase access to terminal PTX groups once bound to gold. However, this 
further complicates the lack of growth inhibition observed in our cell culture assays. As 
cell culture media used in these experiments is supplemented with the same FBS used in 
the release study, a similar hydrolysis profile for PTX should be observed, leading to 
similar inhibitive capabilities unless AuNPs do not remain in extracellular media for an 
extended period of time (i.e. rapid cellular uptake). Hence the disappearance of 
biological activity may arise from the inability of esterases to access surface-bound PTX 
upon cellular internalization through other unidentified interactions. 
3.7. Conclusions 
We have reported the development of a novel PTX-AuNP system based on a 
prodrug strategy aimed at drug release via esterase catalyzed hydrolysis. Selection of the 
C-2' hydroxyl as the point of linker attachment is advantageous as the synthetic sequence 
negates the need for silyl protection strategies employed previously, greatly increasing 
accessibility to a number of analogous constructs. In addition to being synthetically 
attractive, this new class of paclitaxel-AuNP conjugates maintains the physical 
characteristics amenable to the detailed structural characterization described in the 
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previous chapter. Susceptibility of these drug loaded nanoparticles to esterase mediated 
degradation was demonstrated upon incubation in FBS, which resulted in the rapid 
release of paclitaxel from the gold surface (ti/2 = 70 minutes) as well as the simultaneous 
degradation of the PTX-Au product. While extracellular conditions can affect the release 
of covalentry bound drug, employing this C-2'ester approach is not an effective strategy 
for the intracellular delivery of PTX based on a AuNP carrier. Because esterases are not 
confined to intracellular locations, the rapid hydrolysis of paclitaxel raises concern 
regarding the stability of our hybrid system while in circulation. Once introduced into the 
blood stream, nanoparticles will immediately be exposed to plasma enzymes capable of 
hydrolyzing PTX prior to reaching the target site, providing no inherent advantage over 
noncovalent encapsulation strategies. 
Considering the significant loss of biological activity observed in cell culture 
assays, we hypothesize that hydrolysis is inhibitied upon cellular internalization of our 
drug loaded nanoparticles. Activity exhibited by intermediates 9 and 11 suggests that 
hydrolysis of the C-2'ester is efficient in the absence of the gold core, leading us to 
believe that unknown interactions may arise in the cellular environment unique to the 
presence of gold that prevent enzyme access. The next chapter focuses on an 
investigation into identifying chemical functionalities capable of rapid degradation under 
intracellular conditions while demonstrating sufficient stability to extracellular agents. 
3.8. Experimental Methods and Materials 
Unless otherwise stated, all starting materials were obtained from commercial 
suppliers and used without further purification. Cells and cell culture supplies were 
purchased from American Type Tissue Culture (ATCC) and processed via supplier 
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directions. Absorbance values for MTT analysis were recorded using a GeneMate 
ELx800 absorbance reader (BioTek) at 570 nm while using a 690 nm filter as a cutoff. 
' H NMR were recorded in CDCI3 using a Bruker 400 MHz spectrometer. Size Exclusion 
Chromatography (SEC) analysis was performed on a Waters Breeze 1515 series liquid 
chromatograph equipped with a dual X absorbance detector (Waters 2487), automatic 
injector, and three styrogel columns (HR1, HR3, HR4) using linear polystyrene standards 
for the calibration curve and tetrahydrofuran (THF) as the mobile phase. 
Thermogravimetric analysis was performed on a TA Instruments TGA Q50. 3.0-6.0 mg 
samples were placed in platinum sample pans and heated under argon atmosphere at a 
rate of 10 °C/min to 100 °C and held for 30 minutes to completely remove residual 
solvent. Samples were then heated to 700 °C at a rate of 10 °C/min. TEM and HRTEM 
imaging was performed on a JEOL 21 OOF transmission electron microscope operating at 
200 kV accelerating voltage. Samples were drop cast from dilute solutions of 10 % THF 
in CH2CI2 onto carbon-coated TEM grids and allowed to dry in open air. Centrifugal 
filters (2 mL capacity) Ultrafree®-CL containing regenerated cellulose membranes with a 
molecular weight cut-off of 30,000 g/mol were purchased from Fisher Scientific Inc. 4-
(N, N-dimethylamino)-pyridinium-4-toluenesulfonate (DPTS) was prepared by mixing 
saturated THF solutions of N,N-dimethylaminopyridine (DMAP) (1 equiv) and p-
toluenesulfonic acid monohydrate (1 equiv) at room temperature. The precipitate was 
filtered, washed several times with THF, and dried under vacuum. 
3.8.1. Synthetic Methods 
Paclitaxel C-2' succinate (9). To a solution of 100 mg paclitaxel in 2 mL of pyridine 
were added 117 mg (10 equiv) of succinic anhydride. Upon anhydride dissolution, 2 mg 
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DMAP (0.15 equiv, cat.) were added to catalyze the reaction. After 4 hours, the product 
solution was diluted with CH2CI2 and extracted with DI H2O until excess succinic 
anhydride was removed as determined by GPC (approx. 6 times). Upon drying over 
Na2SC>4, the solvent concentration was reduced under vacuum and final product 9 was 
precipitated from hexanes yielding 106 mg of a white powder (95%). *H NMR (CDCI3) 
5 1.14 (s, 3H), 1.25 (s, 3H), 1.69 (s, 3H), 1.91-1.93 (broad, 4H), 2.15 (m, 1H), 2.23 (s, 
3H), 2.45 (m, 1H), 2.50-2.70 (broad, 4H)a, 3.83 (d, 1H), 4.21 (d, 1H), 4.32 (d, 1H), 4.40 
(m, 1H), 4.80 (s, 1H), 5.00 (d, 1H), 5.54 (d, 1H), 5.69 (d, 1H), 6.00 (d, 1H), 6.20-6.30 (m, 
2H), 7.14 (d, 1H), 7.33 (m, 3H), 7.41 (m, 4H), 7.50 (m, 3H), 7.60 (m, 1H), 7.74 (d, 2H), 
8.14 (d,2H). Succinate protons. 
Compound 10. Under vigorous stirring, 20 mg (1.3 equiv) of DPTS were added to a 
solution containing 50 mg of succinate derivative 9 and 32 mg (1.5 equiv) of 
commercially available hexaethylene glycol carboxylic acid ^-butyl ester. After 
dissolution of above components, 33 mg (5 equiv) of DIPC were added to initiate 
coupling. GPC analysis showed the reaction to be complete after 2 hours, at which time 
DPTS and excess HEG linker were removed by 4 extractions with DI H2O. The mixture 
was dried over Na2SC<4 and CH2CI2 was removed under vacuum while DIPC was 
removed by washing the product hexanes. The product was further isolated by column 
chromatography eluting with a 3% solution of MeOH in EtOAc, providing 55 mg (78% 
yield) of 10 as a white solid. Rf = 0.60. !H NMR (CDC13) 5 1.14 (s, 3H), 1.25 (s, 3H), 
1.43 (s, 9H)b, 1.69 (s, 3H), 1.91-1.93 (broad, 4H), 2.15 (m, 1H), 2.23 (s, 3H), 2.45 (m, 
1H), 2.50-2.70 (broad, 4H)\ 3.60 (m, 20H)C, 3.71 (t, 2H)C, 3.83 (d, 1H), 4.10 (m, 2H)C, 
4.21 (d, 1H), 4.32 (d, 1H), 4.40 (m, 1H), 4.80 (s, 1H), 5.00 (d, 1H), 5.54 (d, 1H), 5.69 (d, 
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1H), 6.00 (d, 1H), 6.20-6.30 (m, 2H), 7.14 (d, 1H), 7.33 (m, 3H), 7.41 (m, 4H), 7.50 (m, 
3H), 7.60 (m, 1H), 7.74 (d, 2H), 8.14 (d, 2H). Vbutyl protons. CHEG protons. 
Compound 11. Removal of the J-butyl protecting group was typically achieved upon the 
addition of 0.50 mL of trifluoroacetic acid (TFA) to a 2 mL solution of intermediate 10 
and 2 equivlents of triethyl silane (TES) in CH2CI2. After 30 minutes, solvent and TFA 
were removed under vaccuum leaving a colorless oil. The deprotected product was then 
precipitated as a white powder and washed twice more with hexanes to remove excess 
TES and f-butyl groups. Quantitative yield. Rf = 0 in 3% MeOH:EtOAc. *H NMR 
(CDCI3) 5 1.14 (s, 3H), 1.25 (s, 3H), 1.69 (s, 3H), 1.91-1.93 (broad, 4H), 2.15 (m, 1H), 
2.23 (s, 3H), 2.45 (m, 1H), 2.50-2.70 (broad, 4H)a, 3.60 (m, 20H)C, 3.71 (t, 2H)C, 3.83 (d, 
1H), 4.10 (m, 2H)C, 4.21 (d, 1H), 4.32 (d, 1H), 4.40 (m, 1H), 4.80 (s, 1H), 5.00 (d, 1H), 
5.54 (d, 1H), 5.69 (d, 1H), 6.00 (d, 1H), 6.20-6.30 (m, 2H), 7.14 (d, 1H), 7.33 (m, 3H), 
7.41 (m, 4H), 7.50 (m, 3H), 7.60 (m, 1H), 7.74 (d, 2H), 8.14 (d, 2H). 
Au(PTX)n (12). Activation of 11 is achieved upon the addition of 10 mg DIPC to a 
solution containing 15 mg of carboxyl-terminated compound 11 and 20 mg of DPTS in 2 
mL of CH2CI2. Immediately following DIPC addition, 0.30 mL of a DMF solution 
containing 5 mg of mercaptophenol-funtionalized AuNPs is quickly introduced (DMF is 
utilized to dissolve AuNPs and should not exceed 30% v/v of the total solution). 
Saturation of the gold surface is typically complete in 3-4 hours as determined by GPC 
analysis of the reaction progress. The reaction is quenched upon extracting DPTS with 
DI H2O and subsequent drying over Na2SC"4. Again, hexane washes are performed to 
remove excess DIPC providing a brown powder. The crude product is then dissolved in 
DMF and placed on regenerated cellulose membranes filters (Millipore, MWCO of 30 
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kDa) for centrifugal filtration. As previously described, 3 rounds of centrifugation at 40 
minutes are all that is required for the complete removal of all excess agents. !H NMR 
(CDCI3) 5 1.14 (s, 3H), 1.25 (s, 3H), 1.43 (s, 9H)b, 1.69 (s, 3H), 1.91-1.93 (broad, 4H), 
2.15 (m, 1H), 2.23 (s, 3H), 2.45 (m, 1H), 2.50-2.70 (broad, 4H)a, 3.60 (m, 20H)C, 3.71 (t, 
2H)C, 3.83 (d, 1H), 4.10 (m, 2H)C, 4.21 (d, 1H), 4.32 (d, 1H), 4.40 (m, 1H), 4.80 (s, 1H), 
5.00 (d, 1H), 5.54 (d, 1H), 5.69 (d, 1H), 6.00 (d, 1H), 6.20-6.30 (m, 2H), 7.14 (d, 1H), 
7.33 (m, 3H), 7.41 (m, 4H), 7.50 (m, 3H), 7.60 (m, 1H), 7.74 (d, 2H), 8.14 (d, 2H). 
Compound 13. To a DMF solution containing 50 mg of succinate intermediate 9 and 30 
mg (1.5 equivalents) of 0-benzotriazole-N,N,N',N',-
tetramethyluroniumhexafluorophosphate (HBTU) were added 14 mg (2 equiv) of DIEA. 
After HBTU was dissolved, a solution of 31 mg (1.5 equiv) of commercially available 
aminohexaethylene glycol carboxylic acid /-butyl ester in 0.50 mL of DMF was added 
dropwise. After two hours, the reaction was completed upon HBTU removal via three DI 
H2O extractions and the remaining solution was dried over Na2SC>4. Interestingly, excess 
linker is also extracted by water, further simplifying purification. The desired product 
was then isolated by column chromatography using a solution of 6:1 v/v EtOAc:MeOH 
as eluent leaving 62 mg of a slightly yellow oil. 85% yield. Rf = 0.70. !H NMR (CDC13) 
5 1.14 (s, 3H), 1.25 (s, 3H), 1.44 (s, 9H)b, 1.69 (s, 3H), 1.91-1.93 (broad, 4H), 2.15 (m, 
1H), 2.23 (s, 3H), 2.45 (m, 1H), 2.50(broad, 2H)a, 2.75 (t, 2H)a, 3.32 (m, 2H)C, 3.47 (m, 
2H)e, 3.60 (m, 20H)C, 3.79 (d, 1H), 4.21 (d, 1H), 4.32 (d, 1H), 4.40 (m, 1H), 4.80 (s, 1H), 
5.00 (d, 1H), 5.43 (d, 1H), 5.69 (d, 1H), 5.90 (d, 1H), 6.15 (t, 1H), 6.79 (s, 1H), 6.49 (d, 
1H), 7.33 (m, 3H), 7.41 (m, 4H), 7.50 (m, 3H), 7.60 (m, 1H), 7.74 (d, 2H), 8.14 (d, 2H). 
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Compound 14. The same conditions described above for t-butyl removal were again 
employed here. Briefly, TFA is added to a solution of 13 and TES in CH2CI2 and 
allowed to react for approximately 30 minutes. Solvent is then removed under vacuum 
pressure and the remaining product precipitated as a white powder from hexanes. 
Quantitative conversion. Rf = 0 in 6:1 v/v EtOAc:MeOH. *H NMR (CDC13) 5 1.14 (s, 
3H), 1.25 (s, 3H), 1.69 (s, 3H), 1.91-1.93 (broad, 4H), 2.15 (m, 1H), 2.23 (s, 3H), 2.45 
(m, 1H), 2.50(broad, 2H)a, 2.75 (t, 2H)a, 3.32 (m, 2H)C, 3.47 (m, 2H)C, 3.60 (m, 20 H)c, 
3.79 (d, 1H), 4.21 (d, 1H), 4.32 (d, 1H), 4.40 (m, 1H), 4.80 (s, 1H), 5.00 (d, 1H), 5.43 (d, 
1H), 5.69 (d, 1H), 5.90 (d, 1H), 6.15 (t, 1H), 6.79 (s, 1H), 6.49 (d, 1H), 7.33 (m, 3H), 
7.41 (m, 4H), 7.50 (m, 3H), 7.60 (m, 1H), 7.74 (d, 2H), 8.14 (d, 2H). 
Au(PTX)n (15). Prior to AuNP addition, 15 mg of intermediate 14 is dissolved in 2 mL 
of CH2CI2 along with 20 mg DPTS. Anhydride formation is then catalyzed by the 
addition of 10 mg DIPC. Immediately following activation, 5 mg of stock 
mercaptophenol-functionalized AuNPs in 0.30 mL of DMF are added. Again, the 
coupling of paclitaxel to the surface of gold nanocrystals is complete after 4 hours as 
determined by GPC. DMF and DPTS are then removed via 3 extractions with DI H20 
before drying the remaining solution over Na2SC>4. Hexane washes are again used to 
remove excess DIPC, resulting in the precipitation of crude product as a light brown 
powder, which is subsequently dissolved in DMF. Three 40 minute rounds of centrifugal 
filtration are performed as described for 11 using regenerated cellulose membranes with a 
size cutoff of 30 kDa. Final purity is again confirmed by GPC. !H NMR (CDCI3) 5 1.14 
(s, 3H), 1.25 (s, 3H), 1.69 (s, 3H), 1.91-1.93 (broad, 4H), 2.15 (m, 1H), 2.23 (s, 3H), 2.45 
(m, 1H), 2.50(broad, 2H)\ 2.75 (t, 2H)a, 3.32 (m, 2H)C, 3.47 (m, 2H)C, 3.60 (m, 20 H)c, 
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3.79 (d, 1H), 4.21 (d, 1H), 4.32 (d, 1H), 4.40 (m, 1H), 4.80 (s, 1H), 5.00 (d, 1H), 5.43 (d, 
1H), 5.69 (d, 1H), 5.90 (d, 1H), 6.15 (t, 1H), 6.79 (s, 1H), 6.49 (d, 1H), 7.33 (m, 3H), 
7.41 (m, 4H), 7.50 (m, 3H), 7.60 (m, 1H), 7.74 (d, 2H), 8.14 (d, 2H). 
3.8.2. Enzymatic Hydrolysis of Surface-Bound Paclitaxel 
In an 8 mL vial equipped with a screw cap were added 5 mL of fetal bovine 
serum (FBS) and placed in an oil bath at 37°C. While stirring at 200 rpm, 1 mL of a 
DMSO solution containing approximately 10 mg of PTX-AuNP 15 was added. 1 mL 
aliquots were then removed at specific time points and mixed with 1.5 mL of EtOAc and 
mixed vigorously for 5 minutes. After which, the phases were allowed to separate and 
the organic fraction was analyzed by GPC for released PTX content. Data was reported 
as percent of total material released vs. time. 
3.8.3. MTT Assay 
MCF-7 breast cancer cells were plated in 96-well plates at a concentration of 
4,000 cells/well (100 uL/well) and allowed to attach for 24 hours. After successful 
attachment, 100 uL of media containing the compounds of interest and free paclitaxel (1, 
2, 5, 10, 25, 50, 100 and 500 nM with respect to paclitaxel) were added to each well, with 
each sample concentration having 5 replicates. 72 hours post treatment, 25 uL of yellow 
MTT solution (5 mg/mL in PBS) were added to each well and incubated at 37°C for 3-4 
hours to allow for sufficient conversion to the blue formazan precipitate. Next, the media 
was removed followed by the addition of 100 uL of DMSO to dissolve the blue formazan 
metabolite. Upon agitating the plates for 2 minutes, absorbance values were recorded 
using a plate reader (Gene Mate, BioTek) equipped with a 570 nm filter. 
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3.8.4, NMR Spectra for Intermediate and Final Compounds 
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Figure 5. 'H NMR spectrum of paclitaxel 2' succinate 9. 
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Figure 6. lH NMR spectrum of PTX 2'succinylhexaethylene glycol ?-butyl ester 10. 
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73 
n H H ( N i O N O ( N c s t c N H o a \ ( i ) c o ^ , n < r i y ) i n ' ^ n ( N H H r ^ f f i a c o c o ( D H { N r ' ( N f * i o o ^ H c s ] c o i D H H H o o o o i n i n ^ ' ^ T ' T ' a ' n M N ' J ^ ' N i f i i D v o i o w w k O T U n o i n i / i i n i n ' j ' r o N H O K n u i N H c o a ) 
a ) c o o ) t ^ r - r - r - i ^ r - r - r - i ^ r - ^ k O i / i i n i n m r o m n o i n m n c M N r M r g N ( M r v i t N N r g r H H H H H o o 
H \ /„ 
J Lk_ J U U U l A_ML_JU Li JUULMIUULJKLL^ 
I • ' • • I ' ' ' ' I ' ' ' ' I ' ' • ' I ' ' ' ' I ' ' ' ' I ' ' ' ' I ' • • ' I " ' • ' I • • ' ' I ' ' ' ' I • ' ' ' I ' ' ' ' I ' ' ' ' I ' ' ' ' I ' • • ' I • • • • 
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 ppm 
A )\> 
o 
o 
CM 
o> 
o 
CM 
h-
-~ 
-
1 -
CM 
? 
k 
e» 
a> 
o 
n o 
o 
*" 
; 
CO 
CO 
o 
\AAA K 
T " 
*" 
i n 
O l 
H 
*-H n *-p h 
A 
* o 
1-
JAKJ i n 
r-
T -
co CM 
T -
o 1© 
CO 
o p h 
IO 
i n 
S 
n o 
* CM 
k 
col 
<*! 
«| 
; 
•A CO 
CM 
AA AA 
u> 
r» 
CM 
CO 
1 " 
CO 
o CO 
H 
en i ^ 
CM 
A 
CM 
CO 
CM 
Figure 10. 'H NMR spectrum of PTX 2' succinylamidohexaethylene glycol carboxylic acid 14. 
74 
rHr^^fH^csivocr^c^(^k00ov^oini^ocsiu30CN-3'oc) iH(\ icx3aoooOTHro^<y\roincr iOvDrHr-4Lr)( v iCTN 
o w r ^ m ^ n c K N t N M t M i n f f i o i c o i o n i N H H H c n c o o o i D o i c M N . - i H H H m o i c D o o o D m c o c o t n c o a ) 
O O r r r h r ^ ^ M O i n O C M M N M I N N I N C M N H H H H H H H ^ H r H r H O O O O O O O O O O O 
AuNP(Paclitaxel 2' HEG COOH)n 
(15) 
[ • • • • I • • • • I • • • • I ' ' ' ' I ' I - • • • I • • ' • I ' ' ' ' I ' • • • I • • • • I ' ' ' ' I ' ' , • • • • i • • . . I i • • .
 ( . . . . I . . . . I . . . i 
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 ppm 
/<y o o 
CM 
r«. 
»-eg 
V 
*"• CO 
• ^ 
\ k 
CM] 
cn 
CM 
o t 
CO 
M o 
p 
\ 
co CM 
CO 
"^ 
M 
CO 
CM 
CO 
1.
0 T™ 
4.4
 "s J oo(fr» 
CM CM 
\ 
o 
a 
CO 
6.2
 CM 
5.
7 
14
.8
 
7.6
 
Figure 11. 'H NMR spectrum of final product AuNP(PTX 2'succinylamidohexaethylene 
glycol)n 15. 
75 
3.9. References 
(1) Stella, V. J.; Himmelstein, K. J. J. Med. Chem. 1980, 23, 1275-1282. 
(2) Nudelman, A.; Levovich, I.; Cutts, S. M.; Phillips, D. R.; Rephaeli, A. J. Med. 
Chem. 2005, 48, 1042-1054. 
(3) Fleming, A. B.; Haverstick, K.; Saltzman, W. M. Bioconjugate Chem. 2004, 15, 
1364-1375. 
(4) Niculescu-Duvaz, I.; Niculescu-Duvaz, D.; Friedlos, F.; Spooner, R.; Martin, J.; 
Marais, R.; Springer, C. J. J. Med. Chem. 1999, 42, 2485-2489. 
(5) Gao, Y.; Katsuraya, K.; Kaneko, Y.; Mimura, T.; Nakashima, H.; Uryu, T. 
Macromolecules 1999, 32, 8319-8324. 
(6) Perumal, O.; Khandarre, J.; Kolhe, P.; Kannan, S.; Lieh-Lai, M.; Kannan, R. M. 
Bioconjugate Chem. 2009, 20, 842-846. 
(7) Tsume, Y.; Hilifinger, J. M ; Amidon, G. L. Mol. Pharm. 2008, 5, 717-727. 
(8) Lavis, D. ACS Chem. Biol. 2008, 3, 203-206. 
(9) Dickson, J. K.; Biller, S. A.; Magnin, D. R.; Petrillo, E. W.; Hillyer, J. W.; Hsieh, 
D. C ; Lan, S-. J.; Rinehart, J. K.; Gregg, R. E.; Kalinowski, S. S.; Harrity, T. W.; 
Jolibois, K. G.; Kunselman, L. K.; Mookhtiar, K. A.; Ciosek, C. P. J. Med. Chem. 
1996,39,661-664. 
(10) Song, X.; Vig, B. S.; Lorenzi, P. L.; Drach, J. C; Townsend, L. B.; Amidon, G. L. 
J. Med. Chem. 2005, 48, 1274-1277. 
76 
(11) Saavedra, J. E.; Shami, P. J.; Wang, L. Y.; Davies, K. M.; Booth, M. N.; Citro, M. 
L.; Keefer, L. K. J. Med. Chem. 2000, 43, 261-269. 
(12) Shen, Y.; Jin, E.; Zhang, B.; Murphy, C. J.; Sui, M.; Zhao, J.; Wang, J.; Tang, J.; 
Fan, M.; Van Kirk, E.; Murdoch, W. J. J. Am. Chem. Soc. 2010,132, 4259-4265. 
(13) Franzesi, G. T.; Ni, B.; Ling, Y.; Khademhosseini, A. J. Am. Chem. Soc. 2006, 
128, 15064-15065. 
(14) Song, X.; Lorenze, P. L.; Landowski, C. P.; Vig, B. S.; Hilfmger, J. M.; Amidon, 
G. L. Mol. Pharm. 2004, 2, 157-167. 
(15) Li, P.; Shaw, B. R. J. Org. Chem. 2005, 70, 2171-2183. 
(16) Liederer, B. M.; Fuchs, T.; Velde, D. V.; Siahaan, T. J.; Borchardt, R. T. J. Med. 
Chem. 2006, 49, 1261-1270. 
(17) Giuntini, F.; Bourre, L.; MacRobert, A. J.; Wilson, M.; Eggleston, I. M. J. Med. 
Chem. 2009, 52, 4026-4037. 
(18) Shamis, M.; Lode, H. N.; Shabat, D. J. Am. Chem. Soc. 2004,126, 1726-1731. 
(19) Wolfe, L. A.; Mullin, R. J.; Laethem, R.; Blumenkopf, T. A.; Cory, M.; Miller, J. 
F.; Keith, B. R.; Humphreys, J.; Smith, G. K. Bioconjugate Chem. 1999, 10, 38-
48. 
(20) Vrudhula, V. M.; Svensson, H. P.; Senter, P. D. J. Med. Chem. 1997, 40, 2788-
2792. 
77 
(21) Leu, Y-. L.; Roffler, S. R.; Chern, J-. W. J. Med. Chem. 1999, 42, 3623-3628. 
(22) Torgov, M. Y.; Alley, S. C ; Cerveny, C. G.; Farquhar, D.; Senter, P. D. 
Bioconjugate Chem. 2005,16, 717-721. 
(23) Doronina, S. O.; Bovee, T. D.; Meyer, D. W.; Miyamoto, J. B.; Anderson, M. E.; 
Morris-Tilden, C. A.; Senter, P. D. Bioconjugate Chem. 2008,19, 1960-1963. 
(24) Wang, Y.; Xin, D.; Liu, K.; Zhu, M.; Xiang, J. Bioconjugate Chem. 2009, 20, 
2214-2221. 
(25) de Groot, F. M. H.; van Berkom, L. W. A.; Scheeren, H. W. J. Med. Chem. 2000, 
43,3093-3102. 
(26) Khandare, J. J.; Jayant, S.; Singh, A.; Chandna, P.; Wang, Y.; Vorsa, N.; Minko, 
T. Bioconjugate Chem. 2006,17, 1464-1472. 
(27) Khmelnitsky, Y. L.; Budde, C.; Arnold, J. M.; Usyatinsky, A.; Clark, D. S.; 
Dordick, J. S. J. Am. Chem. Soc. 1997,119, 11554-11555. 
(28) Ansell, S. M.; Johnstone, S. A.; Tardi, P. G.; Lo, L.; Xie, S.; Shu, Y.; Harasym, T. 
O.; Harasym, N. L.; Williams, L.; Bermudes, D.; Liboiron, B. D.; Saad, W.; 
Prud'homme, R. K.; Mayer, L. D. J. Med. Chem. 2008, 51, 3288-3296. 
(29) Wrasidlo, W.; Gaedicke, G.; Guy, R. K.; Renaud, J.; Pitsinos, E.; Nicolaou, K. C ; 
Reisfeld, R. A.; Lode, H. N. Bioconjugate Chem. 2002, 13, 1093-1099. 
(30) Skwarczynski, M.; Hayashi, Y.; Kiso, Y. J. Med. Chem. 2006, 49, 7253-7269. 
78 
(31) Hwu, J. R.; Lin, Y. S.; Josephrajan, T.; Hsu, M-. H.; Cheng, F-. Y.; Yeh, C-. S.; 
Su, W-. C ; Shieh, D-. B. J. Am. Chem. Soc. 2009,131, 66-68. 
(32) Greenwald, R. B.; Zhao, H.; Reddy, P. J. Org. Chem. 2003, 68, 4894-4896. 
(33) Greenwald, R. B.; Gilbert, C. W.; Pendri, A.; Conover, C. D.; Xia, J.; Martinez, 
A. J. Med. Chem. 1996, 39, 424-431. 
(34) Ndungu, J. M.; Lu, Y. J.; Zhu, S.; Yang, C.; Wang, X.; Chen, G.; Shin, D. M.; 
Snyder, J. P.; Shoji, M.; Sun, A. J. Med. Chem. 2010, 53, 3127-3132. 
(35) Safavy, A.; Georg, G. I.; Velde, D. V.; Raisch, K. P.; Safavy, K.; Carpenter, M.; 
Wang, W.; Bonner, J. A.; Khazaeli, M. B.; Buchsbaum, D. J. Bioconjugate Chem. 
2004,15, 1264-1274. 
(36) Lee, H.; Lee, K.; Park, T. G. Bioconjugate Chem. 2008, 19, 1319-1325. 
(37) Lin, Y-. S.; Tungpradit, R.; Sinchaikul, S.; An, F-. M.; Liu, D-. Z.; Phutrakul, S.; 
Chen, S-. T. J. Med. Chem. 2008, 57, 7428-7441. 
(38) Safavy, A.; Raisch, K. P.; Matusiak, D.; Bhatnagar, S.; Helson, L. Bioconjugate 
Chem. 2006, 77,565-570. 
(39) Zhao, Z.; Kingston, D. G. I. J. Nat. Prod. 1991, 54, 1607-1611. 
(40) Deutsch, H. M.; Glinski, J. A.; Hernandez, M.; Haugwitz, R. D.; Narayanan, V. 
L.; Suffness, M.; Zalkow, L. H. J. Med. Chem. 1989, 32, 788-792. 
79 
(41) Skwarczynski, M ; Sohma, Y.; Noguchi, M.; Kimura, M.; Hayashi, Y.; Hamada, 
Y.; Kimura, T.; Kiso, Y. J. Med. Chem. 2005, 48, 2655-2666. 
(42) Rodrigues, M. L.; Carter, P.; Wirth, C ; Mullins, S.; Lee. A.; Blackburn, B. K. 
Chem. Biol. 1995, 2, 223-227. 
(43) Zakharian, T. Y.; Seryshev, A.; Sitharaman, B.; Gilbert, B. E.; Knight, V.; 
Wilson, L. J. J. Am. Chem. Soc. 2005,127, 12508-12509. 
Chapter 4: Release of Surface-Bound Paclitaxel by Intracellular 
Glutathione Reduction of a Disulfide Linker 
4.1. Introduction 
Primarily functioning as a protective agent against harmful oxidative species, 
glutathione (GSH) is an endogenous tripeptide found in high concentrations throughout 
the cytoplasm of cells.1"4 Owing to a highly nucleophilic thiol, GSH's protective action 
results from the ability to bind to foreign compounds, preventing their reaction with 
various proteins and potential interference with normal cell activity. Interestingly, 
intracellular GSH concentrations have been found to be as much as three orders of 
magnitude higher than extracellular levels, giving rise to GSH reduction as a promising 
mechanism in the design of prodrugs aimed at intracellular delivery of therapeutic 
agents.5"11 Exceedingly susceptible to nucleophilic attack by GSH, disulfide bonds have 
been utilized to link drug molecules to targeting agents such as antibodies and peptides 
and have been shown to efficiently release compounds under said reductive conditions. 
17
 Additionally, classic work by Rotello and coworkers has demonstrated the ability of 
GSH to displace thiol terminated species from the surface of gold nanoparticles through a 
place exchange process.18"21 The propensity of glutathione to displace surface-bound 
ligands has been exploited in functional nanoparticle systems towards gene delivery as 
well as the reactivation of DNA transcription. 
Structurally, our previous Au-PTX constructs are similar to those developed by 
Rotello and coworkers in that biologically active molecules are covalently bound to the 
surface of gold nanoparticles through a gold-sulfur bond. If indeed glutathione 
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displacement of surface-bound ligands is quantitiative, then the growth inhibition 
observed for AuNP systems described in the preceding chapter should more closely 
resemble the activity measured for succinate compounds 11 and 14 prior to their 
attachment to nanoparticles. Unfortunately, we observe a drastic decrease in activity 
upon the grafting of said analogs to AuNPs. As suggested for our PTX-2' succinate 
derivatives, there may exist some unidentified interactions in the cellular environment 
that physically inhibit glutathione access to the surface of AuNPs. However, 
incorporating a disulfide functionality away from the crowded gold surface may enhance 
GSH accessibility hence, intracellular drug release. Additionally, the smaller size of 
glutathione relative to esterases may increase GSH-linker interactions, resulting in a more 
efficient release of paclitaxel from AuNPs (Figure 1). 
Figure 1. Proposed mechanism for the glutathione mediated cleavage of a disulfide linker. 
4.2. Synthesis of Paclitaxel-Functionalized AuNPs Featuring a Disulfide Linker 
Introduction of a disulfide moiety into the linker requires only minor modification 
of our previous synthetic scheme. Motivation for inclusion of an SS bond near the 
terminal PTX groups is twofold in that GSH access will be maximized and the 
intermediate structure resulting from reduction will closely resemble PTX-2'succinate 9, 
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Scheme 1. Synthesis of a paclitaxel analog featuring a disulfide moiety at the C-2' 
postion (top). Subsequent coupling of new analog to the surface of 2 nm AuNPs. 
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which exhibits identical cellular toxicity as free pactlitaxel upon hydrolysis. 
Additionally, cleavage of the disulfide bond in dithiodibutyric acid (DTDBA) provides a 
thiol terminated intermediate capable of instantaneous cyclization, further enhancing the 
potential of paclitaxel release (Figure 1). Esterification of the C-2' hydroxyl of PTX with 
monotriispropylsilyl dithiodibutyrc acid is efficient under standard coupling conditions 
(Scheme 1) and is followed by treatment with HF/pyridine (70:30 v/v) affording carboxyl 
terminated intermediate 17 in 83% yield. Amide formation is accomplished by coupling 
17 with commercially available aminohexaethylene glycol carboxylic acid /-butyl ester in 
the presence of HBTU and DIEA. The final step in the synthesis of PTX-SS linker 19 is 
complete upon the removal of the /-butyl protecting group via treatment with TFA. 
Again, coupling of 19 to the stock mercaptophenol-functionalized AuNPs is performed 
under the standard DIPC/DPTS conditions described previously. Upon loading PTX onto 
the surface of particles, 20 is dissolved in DMF and placed on regenerated cellulose 
membrane filters and purified by centrifugal filtration. Confirmation of purity by GPC is 
followed by structural analysis by 'H NMR and the amount of bound paclitaxel is 
quantified by TGA. 
4.3. Investigation into the Release of Surface-Bound Paclitaxel via Glutathione 
Reduction 
Prior to measuring cytotoxicity, we first wanted to qualitatively study the ability 
of PTX-Au 20 to release paclitaxel under GSH reductive conditions. For this experiment, 
the disulfide containing product was exposed to intracellular GSH levels (lOmM) and 
incubated at 37°C for 24 hours. Aliquots were taken at various time points and analyzed 
for free PTX content by GPC and plotted as a percent of total released material vs. time 
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(Figure 3). Upon analysis of the initial sample taken at 15 minutes, we were surprised to 
see the appearance of a high molecular weight signal corresponding to the mass of drug-
linker intermediate 19, while observing virtually no amount of the signal corresponding 
to the lower mass disulfide reduction product (Figure 2). Consistent with these 
preliminary results, glutathione is known to display the capability to efficiently displace 
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Figure 2. GPC traces tracking the GSH-mediated release of surface-bound ligands. Initially, the 
entire thiol-terminated ligand (*) is displaced followed by the appearance of the disulfide 
reduction product (**). 
thiol-terminated ligands from the surface of gold nanoparticles. However, this suggests 
that GSH possesses a significantly higher affinity for the gold surface relative to the 
disulfide linker, which is somewhat unexpected in this case as the more densely packed 
surface of particles should be physically less accessible. Additionally, this indicates that 
GSH bypasses the terminal disulfide linker before interacting with Au-thiol bonds. 
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While it is unlikely that disulfide cleavage is not taking place, it is concluded from these 
initial data that the rate of disulfide reduction is significantly lower than displacement of 
thiols at the gold surface within this range of GSH concentrations. Further supporting the 
notion of preferential attack of the gold surface is the rapid degradation and subsequent 
disappearance of the signal corresponding to the AuNP product 20. In the experiments 
based on esterase activity, the nanoparticle signal was observed to broaden as well as 
Glutathione Mediated PTX Release 
£ 
120 i 
100 
80 -
60 -
40 A • 
20 A 
0 
• 
1
 • • 
* * • PTX 
• PTX2'SSHEGSH 
9 
• 
0 4 
- i 1 1 — 
8 12 16 
Time (h) 
20 24 
Figure 3. Release of surface-bound ligands due to GSH displacement. The two traces represent 
the disappearance of the entire thiol-terminated ligand (magenta) as the disulfide reduction 
product appears (blue). 
decrease in area over time as the removal of terminal PTX groups increased the water 
solubility of the particles thereby, decreasing their ability to be extracted into organic 
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solvents. However, the signal for 20 virtually disappears within the first 30 minutes, 
indicative of an instantaneous and complete modification in surface structure. Although 
unexpected, these initial results demonsrate the accessibility of the nanoparticle surface to 
small molecules such as GSH. 
GPC traces taken at later time points show the subsequent degradation of this 
higher mass peak as a lower molecular mass peak appears (Figure 3), corresponding to 
the disulfide reduction product. It should be noted that we did not attempt to identify the 
structure of the lower mass signal to determine if indeed cyclization of the remaining 
butyrate portion occurs. While the appearance of the high mass peak is seemingly 
instantaneous, the rate of conversion to the lower mass peak is also relatively fast with a 
half-time of appearance being approximately 70 minutes, supporting the hypothesis that 
GSH reduction of disulfide bonds is efficient. In fact, more than 80% of free drug 
appears within the first 3 hours, confirming the potential utility of a release strategy based 
on GSH reduction. Interestingly, the results of the above release study confirm two sites 
in the structure of our hybrid AuNP system capable of degradation in the presence of 
intracellular levels of glutathione. 
4.4. Measuring the in vitro Cytotoxicity of AuNP 20 
Having demonstrated the efficient release of PTX based on GSH reduction, 
comparative cell culture experiments were performed to measure the antiproliferative 
effects of PTX-AuNP 20 on MCF-7 breast cancer cells. As before, intermediate 
compounds 17 and 19 were also analyzed to observe any change in toxicity resulting 
from the chemical processing of starting paclitaxel. Cells were treated with a range of 
concentrations of each compound and mitochondrial activity measured 3 days post 
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treatment via standard MTT protocol. Data is shown in Figure 4 below. Consistent with 
the results observed for PTX-2'succinate 9, compound 17 exhibits similar activity to the 
parent drug, providing further evidence that C-2' esterification does not significantly alter 
biological activity. This can be expected since PTX release and subsequent activation is 
not governed exclusively by GSH reduction as 17 is also susceptible to the same esterase 
hydrolysis as its succinate derivative. However, a hydrolytic process alone is not 
consistent with the increased activity exhibited by intermediate 19 (IC5o 30-40 nM) when 
compared to the structurally similar PTX-2' succinate derivative 11 tested previously 
Growth Inhibition of MCF-7 Breast Carcinoma 
0 100 200 300 
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Figure 4. Observed growth inhibition for final product 20 as well as intermediate compounds 17 
and 19 vs. MCF-7 breast cancer cells. Paclitaxel is also shown as the control. 
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(IC50 60-70 nM). We described the inclusion of a HEG moiety as causing a significant 
decrease in toxicity, which is attributed to the ability of HEG to actively shield paclitaxel 
from enzymatic hydrolysis. The two-fold increase in activity observed for disulfide 19 
indicates a lesser ability of HEG to interfere with GSH activity, allowing for greater 
linker-reductant interaction and a more efficient release of PTX. Although adequate 
toxicity is associated with intermediates 17 and 19, a familiar trend is observed upon 
conjugation of 19 to the surface of AuNPs. As shown in Figure 4, the final product 20 
essentially exhibits a complete loss of biological activity. This result is discouraging in 
view of not only the inhibitive properties of intermediate compounds but also the 
observed susceptibility of our hybrid system to GSH-mediated release at intracellular 
concentrations. Given the instantaneous discharge of surface-bound ligands observed in 
the release studies, the activity of final product 20 would be expected to more closely 
resemble that reported for intermediate 19. Unfortunately, this is not observed in this 
experiment. These results do suggest that introduction of the gold core causes a drastic 
change in behavior of the hybrid system within the cellular environment. Consequently, 
there must exist some interactions unique to the presence of the metallic nanoparticle that 
prohibit GSH access to both the terminal disulfide groups and the surface Au-thiol bonds. 
4.5. Conclusions 
Previous work has focused on establishing a strategy aimed at the release of 
covalently bound paclitaxel from the surface of gold nanoparticles utilizing the common 
prodrug approach of esterification at the C-2' hydroxyl. While capable of efficient 
release of PTX through endogenous esterase hydrolysis, it is necessary to provide an 
alternative method employing intracellular agents to release PTX exclusively upon 
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cellular internalization. We have prepared an analogous PTX-AuNP system 
incorporating a disulfide linker dependent upon intracellular concentrations of GSH for 
the efficient release of bound drug. In the presence of 10 mM glutathione, final product 
20 undergoes instantaneous surface modification caused by a place exchange reaction 
with GSH, resulting in the expulsion of thiol terminated ligands prior to disulfide 
reduction. This is a significant observation as we are confident that steric interactions do 
not play a role in prohibiting small molecules from interacting with the Au surface or its 
bound ligands. 
Interestingly, significant retention of PTX cytotoxicity is maintained by all 
intermediate compounds as evidenced by results obtained in cell culture experiments. 
However, upon grafting of intermediate 19 to AuNPs, a drastic decrease in efficacy is 
observed. Coupled with the high susceptibility to GSH reduction, this disappearance of 
activity suggests that 20 does not encounter a GSH rich environment upon cellular 
internalization. The inability to inhibit cell growth must then arise due to biological 
interactions unique to the Au core rather than the inefficiency of linker functionality. 
Results of the experiments described in this chapter indicate the need to investigate the 
inherent behavior of AuNPs in the cellular environment. If AuNPs do not encounter 
sufficient levels of neither esterase enzymes nor GSH for efficient cleavage based on 
previous strategies, then the location of nanoparticles upon internalization must be 
studied. An understanding of the endogenous chemical environment surrounding our 
drug loaded nanoparticles must be obtained in order to rationally design a linker capable 
of efficient degradation and subsequent payload release. Additional cell culture 
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experiments and strategies employed to effect intracellular paclitaxel release are 
addressed in the following chapter. 
4.6. Experimental Methods and Materials 
Unless otherwise stated, all starting materials were obtained from commercial 
suppliers and used without further purification. Cells and cell culture supplies were 
purchased from American Type Tissue Culture (ATCC) and processed via supplier 
directions. Absorbance values for MTT analysis were recorded using a GeneMate 
ELx800 absorbance reader (BioTek) at 570 nm while using a 690 nm filter as a cutoff. 
*H NMR were recorded in CDCI3 using a Bruker 400 MHz spectrometer. Size Exclusion 
Chromatography (SEC) analysis was performed on a Waters Breeze 1515 series liquid 
chromatograph equipped with a dual X absorbance detector (Waters 2487), automatic 
injector, and three styrogel columns (HR1, HR3, HR4) using linear polystyrene standards 
for the calibration curve and tetrahydrofuran (THF) as the mobile phase. 
Thermogravimetric analysis was performed on a TA Instruments TGA Q50. 3.0-6.0 mg 
samples were placed in platinum sample pans and heated under argon atmosphere at a 
rate of 10 °C/min to 100 °C and held for 30 minutes to completely remove residual 
solvent. Samples were then heated to 700 °C at a rate of 10 °C/min. TEM and HRTEM 
imaging was performed on a JEOL 21 OOF transmission electron microscope operating at 
200 kV accelerating voltage. Samples were drop cast from dilute solutions of 10 % THF 
in CH2CI2 onto carbon-coated TEM grids and allowed to dry in open air. Centrifugal 
filters (2 mL capacity) Ultrafree®-CL containing regenerated cellulose membranes with a 
molecular weight cut-off of 30,000 g/mol were purchased from Fisher Scientific Inc. 4-
(N, N-dimethylamino)-pyridinium-4-toluenesulfonate (DPTS) was prepared by mixing 
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saturated THF solutions of N,N-dimethylaminopyridine (DMAP) (1 equiv) and p-
toluenesulfonic acid monohydrate (1 equiv) at room temperature. The precipitate was 
filtered, washed several times with THF, and dried under vacuum. 
4.6.1. Synthetic Methods 
Monotriisopropylsilyl dithiodibutyric acid. To a 5 mL solution containing 620 mg (5 
equiv) dithiodibutyric acid (DTDBA) in DMF were added 50 mg (1.1 equiv) of the base 
morpholine. While stirring vigorously, 100 mg of triisopropylsilyl chloride (TIPSC1) 
were added dropwise. Following 1 hour of reaction time, the crude product mixture was 
diluted with 10 mL of CH2CI2 and DMF and morpholine were extracted upon washing 
with DI water (4 times) and a 3% aqueous solution of citric acid (twice). After DMF 
removal, the solvent is filtered as excess DTDBA is not soluble in methylene chloride, 
and crashes out of solution and dried over Na2SC>4. The desired product is then purified 
via column chromatography eluting with 15% THF in CH2CI2, leaving 139 mg of a 
colorless oil. 71% yield. Rf=0.60. *H NMR (CDC13) 5 1.10 (d, 18H), 1.28 (m, 3H), 2.0 
(m, 4H), 2.46 (m, 4H), 2.70 (m, 4H). 
Paclitaxel 2' dithiodibutyrate monotriisopropyl silane (16). In an 8 mL vial, 50 mg of 
paclitaxel were dissolved in 3 mL of CH2CI2. 35 mg (1.5 equiv) of DTDBA-TIPS were 
then added, followed by the dissolution of 35 mg (2 equiv) of DPTS. After all 
components were observed in solution, 30 mg (5 equiv) of DIPC were added to catalyze 
anhydride formation. The reaction was monitored by TLC and found to be complete 
after two hours. Please note that not all starting PTX is consumed as the reaction is 
quenched upon the appearance of the bifunctionalized product. DPTS is subsequently 
removed via 3 DI water extractions and the solution is then dried over Na2SC>4. The 
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product is then isolated by column chromatography using a 1:1 v/v mixture of 
EtOAc:Hexanes as the eluent. Rf=0.70. This reaction typically yields approximately 60 
mg (84%) of a white powder. [H NMR (CDC13) 5 1.10 (d, 18H)a, 1.14 (m, 3H), 1.25 (s, 
3H), 1.28 (m, 3H)a, 1.69 (s, 3H), 1.91-1.93 (broad, 4H), 2.00 (m, 4H), 2.15 (m, 1H), 2.23 
(s, 3H), 2.45 (m, 1H), 2.48 (m, 4H), 2.70 (m,4H), 3.83 (d, 1H), 4.21 (d, 1H), 4.32 (d, 1H), 
4.45 (m, 1H), 5.00 (d, 1H), 5.50 (d, 1H), 5.69 (d, 1H), 6.00 (d, 1H), 6.20-6.30 (m, 2H), 
6.93 (d, 1H), 7.38 (m, 7H), 7.50 (m, 3H), 7.50 (m, 3H), 7.60 (m, 1H), 7.74 (d, 2H), 8.15 
(d,2H). aTIPS protons. 
Compound 17. 50 mg of paclitaxel2'DTDBA-TIPS 16 were dissolved in 2 mL of THF 
and added to a 8 mL polypropylene vial equipped with a screw cap. While stirring 
vigorously, 0.50 mL of HF in pyridine (70:30 v/v respectively) were quickly added. The 
vial instantly became warm to the touch upon HF addition. The reaction was allowed to 
proceed for 45 minutes prior to dilution with 3-4 mL of CH2CI2. The HF/pyridine 
reactant is removed by washing the solution 4 times with DI water. The remaining 
solution is then concentrated under vacuum and the product precipitated from hexanes. 
The white powder is then washed twice more to ensure removal of HF and any cleaved 
silyl groups. TLC is then checked again in 1:1 EtOAc:Hexanes showing quantitiative 
removal of the TIPS group. Rf=0. 'H NMR (CDC13) 5 1.14 (m, 3H), 1.25 (s, 3H), 1.69 
(s, 3H), 1.91-1.93 (broad, 4H), 2.15 (m, 1H), 2.23 (s, 3H), 2.45 (m, 1H), 3.83 (d, 1H), 
4.21 (d, 1H), 4.32 (d, 1H), 4.45 (m, 1H), 5.00 (d, 1H), 5.56 (d, 1H), 5.69 (d, 1H), 6.00 (d, 
1H), 6.20-6.30 (m, 2H), 7.12 (d, 1H), 7.38 (m, 7H), 7.50 (m, 3H), 7.50 (m, 3H), 7.60 (m, 
1H), 7.74 (d,2H), 8.15 (d,2H). 
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Comound 18. In an 8 mL vial 50 mg 17 and 25 mg (1.3 equiv) of commercially 
available aminohexaethylene glycol carboxylic acid ?-butyl ester were dissolved in 2 mL 
of DMF. 26 mg (1.5 equiv) of HBTU were then added to the mixture and allowed to 
activate coupling. After 10 minutes, 12 mg (2 equiv) of DIEA were added and the 
reaction was monitored by GPC. After 2 hours, amide formation was found to be near 
quantitative and the solution was diluted with CH2CI2 and extracted three times with DI 
water. The product was further purified via column chromatography eluting with a 6:1 
mixture of EtOAc and MeOH and dried under vacuum resulting in 58 mg (86%) of a 
white powder. Rf=0.60. 'H NMR (CDCI3) 5 1.14 (m, 3H), 1.25 (s, 3H), 1.69 (s, 3H), 
1.91-1.93 (broad, 4H), 2.15 (m, 1H), 2.23 (s, 3H), 2.45 (m, 1H), 3.83 (d, 1H), 4.21 (d, 
1H), 4.32 (d, 1H), 4.45 (m, 1H), 5.00 (d, 1H), 5.56 (d, 1H), 5.69 (d, 1H), 6.00 (d, 1H), 
6.20-6.30 (m, 2H), 7.12 (d, 1H), 7.38 (m, 7H), 7.50 (m, 3H), 7.50 (m, 3H), 7.60 (m, 1H), 
7.74 (d, 2H), 8.15 (d,2H). 
Compound 19. To a 2 mL solution of 50 mg of 18 in CH2CI2 were added 11 mg of 
triethylsilane (2 equiv). Removal of the f-butyl group is then initiated upon the addition 
of 0.50 mL of TFA. After 30 minutes, the solvent and TFA are removed under vacuum 
and the resulting colorless oil washed three times with hexanes to remove any residual 
TFA as well as TES and any removed f-butyl groups. Rf= 0 in 6:1 EtOAc:Hexanes. 'H 
NMR (CDCI3) 5 1.14 (m, 3H), 1.25 (s, 3H), 1.69 (s, 3H), 1.91-1.93 (broad, 4H), 2.15 (m, 
1H), 2.23 (s, 3H), 2.45 (m, 1H), 3.83 (d, 1H), 4.21 (d, 1H), 4.32 (d, 1H), 4.45 (m, 1H), 
5.00 (d, 1H), 5.56 (d, 1H), 5.69 (d, 1H), 6.00 (d, 1H), 6.20-6.30 (m, 2H), 7.12 (d, 1H), 
7.38 (m, 7H), 7.50 (m, 3H), 7.50 (m, 3H), 7.60 (m, 1H), 7.74 (d, 2H), 8.15 (d, 2H). 
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Au(PTX)n (20). 15 mg of carboxyl terminated intermediate 19 were first dissolved in 2 
mL of CH2C12 followed by the dissolution of 25 mg of DPTS. 12 mg of DIPC were then 
introduced to catalyze anhydride formation. Immediately, a solution of 5 mg of stock 
mercaptophenol-coated nanoparticles in DMF was added. Typically, the reaction was 
determined to be complete after 3-4 hours by GPC analysis. DPTS and DMF were then 
removed via three extractions was DI water and the remaining solution was dried over 
Na2SC>4. Methylene chloride was removed under vacuum and DIPC removed upon 
precipitating the product from hexanes. The light brown powder was dissolved in DMF 
and placed on regenerated cellulose centrifuge membranes (Millipore MWCO of 30 kDa) 
and centrifuged at 3,700 rpm for three rounds at 40 minutes each. Complete removal of 
excess coupling agents was confirmed again by GPC. Total mass of product obtained in 
this reaction was 14 mg of a brown powder. *H NMR (CDC13) 5 1.14 (m, 3H), 1.25 (s, 
3H), 1.69 (s, 3H), 1.91-1.93 (broad, 4H), 2.15 (m, 1H), 2.23 (s, 3H), 2.45 (m, 1H), 3.83 
(d, 1H), 4.21 (d, 1H), 4.32 (d, 1H), 4.45 (m, 1H), 5.00 (d, 1H), 5.56 (d, 1H), 5.69 (d, 1H), 
6.00 (d, 1H), 6.20-6.30 (m, 2H), 7.12 (d, 1H), 7.38 (m, 7H), 7.50 (m, 3H), 7.50 (m, 3H), 
7.60 (m, 1H), 7.74 (d, 2H), 8.15 (d, 2H). 
4.6.2. GIutathione-Mediated Release of Surface-Bound Paclitaxel 
In an 8 mL screw cap vial was added a 1 mL solution of PTX-AuNP 20 in 
DMSO. Upon diluting to a final volume of 6 mL with cell culture grade water the vial 
was placed in an oil bath at 37°C. Reduced glutathione was then added to a final 
concentration of 10 mM and gently stirred at 200 rpm. 1 mL aliquots were taken at 
predetermined time points and mixed vigorously with 1.5 mL of CH2CI2 for 5 minutes. 
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Fractions were then allowed to separate and the organic layer was analyzed by GPC for 
release PTX content. Data was reported as percent of total released material vs. time. 
4.6.3. MTT Assay 
MCF-7 breast cancer cells were plated in 96-well plates at a concentration of 
4,000 cells/well (100 uL/well) and allowed to attach for 24 hours. After successful 
attachment, 100 uL of media containing the compounds of interest and free paclitaxel (1, 
2, 5, 10, 25, 50, 100 and 500 nM with respect to paclitaxel) were added to each well, with 
each sample concentration having 5 replicates. 72 hours post treatment, 25 uL of yellow 
MTT solution (5 mg/mL in PBS) were added to each well and incubated at 37°C for 3-4 
hours to allow for sufficient conversion to the blue formazan precipitate. Next, the media 
was removed followed by the addition of 100 uL of DMSO to dissolve the blue formazan 
metabolite. Upon agitating the plates for 2 minutes, absorbance values were recorded 
using a plate reader (Gene Mate, BioTek) equipped with a 570 nm filter. 
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4.6.4. NMR Spectra for Intermediate and Final Compounds 
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Chapter 5: Synthesis of a Paclitaxel-AuNP Conjugate Featuring an Acid 
Sensitive Hydrazone Linker 
5.1. Introduction 
Successful development of an intracellular delivery system based on metallic 
nanoparticles is reliant upon understanding of the cellular mechanism involved in carrier 
uptake and processing. As previously described, we have designed several analogous 
PTX-Au conjugates incorporating common prodrug strategies aimed at the in vivo release 
of therapeutic content based on natural biological processes. While demonstrating the 
capability of paclitaxel separation under ideal conditions, these systems fall short in the 
cellular environment. Adequate toxicity exhibited by PTX intermediates prior to linking 
to the Au core suggests that the inability of these hybrid systems to inhibit cell 
proliferation directly corresponds to the presence of the metal nanoparticles themselves. 
As a result, the rational design of an efficacious gold nanoparticle delivery system relies 
primarily on an awareness of the immediate chemical environment upon cellular 
internalization. Due to the numerous potential biological applications of nanomaterials, 
the intracellular fate of AuNPs has attracted considerable attention and has been the focus 
of recent investigations in the literature.1"10 Regardless of variations in the size, shape 
and surface chemistry of AuNPs, the majority of reported work describes their efficient 
uptake and internalization as driven by an endocyitic mechanism. While capable of 
influencing the rate of endocytosis, altering the physical characteristics of nanoparticle 
systems does not significantly impact their internalization via endosomal containment. 
Perhaps most important, this observed encapsulation of AuNPs by endosomes limits their 
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accessibility to cellular agents and processes, which has become a primary concern in the 
area of bionanomaterials and more specifically, small molecule delivery. 
Interestingly, a small number of recent reports have focused on the strategic 
development of nanoparticle systems capable of endosomal escape, thereby increasing 
the fraction of nanoparticles present in the cytosol.12"17 Incorporation of nuclear targeting 
peptides such as large T antigens onto the surface of AuNPs is one example of increasing 
the number of particles interacting with the nuclear membrane. A pioneer in the field of 
metallic nanoparticle synthesis, Mathias Brust has recently demonstrated liposomal 
delivery of AuNPs as a successful alternative for cytosolic access.18 Unfortunately, while 
possessing the capability to increase the number of nanoparticles in the cytoplasm, these 
strategies require complex structural modification rendering the synthesis of said systems 
increasingly difficult. Additionally, these methods do not result in the quantitative 
avoidance of endosomal encapsulation for all metallic particles, hence limiting their 
utility as an approach for efficient intracellular drug delivery. 
Given the inherent propensity of AuNPs to be internalized by cells as well as the 
difficulties associated with endosomal evasion, the following work focuses on an 
investigation into the feasibility of effecting paclitaxel release by exploiting the chemical 
characteristics unique to the endosomal environment. The ultimate goal of this effort is 
the design of a AuNP-linker system that can quantitatively deliver paclitaxel while 
maintaining synthetic simplicity. Functioning as a protective component of cells, it is 
believed that endosomes primarily serve to trap foreign materials in order to prevent their 
potential interference with normal cellular activity. However, reports on the nature of the 
endosomal interior reveal an environment that is extremely acidic, some of which 
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describe pH values as low as 5.19 Interestingly, pH sensitive analogs have been 
developed for various drug molecules such as the chemotherapeutic doxorubicin, which 
rapidly degrade upon encountering an acidic environment like that found in tumorous 
tissue.20"29 Highly responsive to slight decreases in pH, hydrazone bonds have been the 
focus of a significant portion of strategies aimed at reactivation of therapeutic agents 
upon entering an acidic environment, while demonstrating remarkable stability at 
physiological pH (Figure 1). Due to the efficiency of acid-catalyzed hydrolysis, 
utilization of a hydrazone linker provides an intracellular delivery strategy that should 
result in a near quantitative delivery of bound paclitaxel as virtually all internalized 
particles will encounter the interior of endosomes. Additionally, the stability of 
hydrazone bonds at neutral pH should reduce the occurrence of premature drug 
dissociation while in circulation. 
9 pH=5-6
 n [J . 
1
 H aqueous | o 
Figure 1. General mechanism illustrating the cleavage of a hydrazone bond under slightly acidic 
conditions. 
5.2. Synthesis of a Hydrazone-Containing Paclitaxel-AuNP Conjugate 
Initial attempts at hydrazone formation were focused on the reaction of hydrazide 
terminated linkers with the carbonyl group located at the C-9 position of paclitaxel. 
Unfortunately, these attempts were unsuccessful due to steric hindrance at this site. 
Motivated by the need to introduce a more accessible carbonyl into the structure of PTX, 
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pyruvic acid was chosen as it can be readily coupled with the C-2' hydroxyl group under 
our standard reaction conditions. Equally attractive, the close proximity of the 
subsequent hydrazone functionality to the terminal PTX groups will result in the 
liberation of PTX-2' pyruvate, which should be susceptible to rapid esterase hydrolysis 
analogous to that demonstrated for both C-2' succinate and dithiodibutyrate systems. 
Scheme 1 illustrates the convergent synthetic strategy employed in the manufacturing of 
the new PTX-AuNP delivery system beginning with the aforementioned conversion of 
paclitaxel to 21 with pyruvic acid under standard DIPC/DPTS conditions. In a separate 
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Scheme 1. Synthesis of a hydrazone containing linker at the C-2' position of paclitaxel. 
synthesis, commercially available aminotetraethylene glycol f-boc-hydrazide is coupled 
with glutaric anhydride in order to introduce a terminal carboxyl group that can be 
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coupled to the surface of mercaptophenol-functionalized AuNPs. Simply dissolving both 
agents in an equimolar ratio resulted in quantitative conversion to the desired product in 
the absence of base or catalyst. Interestingly, the entire carboxyl terminated, free 
hydrazide linker is produced in a one pot synthesis as TFA (20% final concentration v/v) 
is subsequently added to the above reaction after one hour to cleave the t-Boc group. 
Hydrazone formation is then achieved upon the reaction of 21 and the hydrazide-
terminated linker in the presence of catalytic amounts of TFA with moderate yields. TLC 
analysis of the reaction reveals the near instantaneous formation of a highly UV active 
product corresponding to the appearance of hydrazone containing intermediate 22. 
Isolation of the desired product is also simplified as any unreacted hydrazide linker is 
removed via water extractions and excess PTX-2' pyruvate is removed upon precipitating 
and rinsing with a 10% solution of EtOAc in hexanes. The synthetic sequence is 
completed upon the coupling of carboxyl-terminated compound 22 to the surface of 
Scheme 2. Covalent grafting of hydrazone analog onto the surface of 2 nm AuNPs. 
109 
mercaptophenol-coated AuNPs using standard DIPC/DPTS conditions. Analogous to 
previous systems, the relative large size of the final product 23 allows for purification via 
centrifugation on regenerated cellulose membranes. Prior to structural analysis, the 
complete removal of excess coupling agents as well as 22 was confirmed by GPC. 
5.3. Histological Study of AuNP Cellular Uptake 
In an attempt to determine the intracellular location of our drug loaded 
nanoparticles upon cellular uptake, a histological study was conducted, which focused on 
the imaging of internalized AuNPs via transmission electron microscopy (TEM). MCF-7 
breast cancer cells were treated with increasing amounts of 23 and incubated for 12 hours 
prior to processing and imaging. Cross-sectional cellular samples measuring 75 nm in 
height are then imaged by TEM for internalized content. Analysis of these cross-sections 
is crucial as it removes the presence of surface-bound nanoparticles and ensures that 
observed particulate material had in fact been internalized. Interestingly, representative 
TEM images confirm not only the presence of a significant amount of internalized 
nanoparticles, but more importantly, their internal compartmentalization (Figure 2). 
While consistent with reported endosomal encapsulation, these images provide 
conclusive evidence that hydrazone product 23 does not have access to the cytosolic 
environment as virtually no gold is observed outside of these confined spaces. These 
initial findings provide insight into the observed lack of toxicity exhibited by our earlier 
strategies. As previously described, the failure of both succinate and dithiodibutyrate 
systems is attributed to their lack of access to intracellular agents required for metabolism 
and subsequent drug cleavage, consistent with the cellular encapsulation and confinement 
observed in this study. 
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In addition to internal compartmentalization, further analysis of TEM images 
reveals the extensive aggregation of 23 within these structures. Considering the process 
of endocytosis as the envelopment of external material by the cell membrane, it is 
;$* 
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Figure 2. Representative TEM images of cells upon incubation with AuNP 23. Images show the 
confinement of drug-loaded gold nanoparticles in endosomal compartments. 
suggested that aggregation occurs prior to internalization. However, the fusion of 
multiple endosomal compartments is a known intracellular process,19 which could also 
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result in the accumulation of several AuNPs in a single endosome observed above. 
Unfortunately, it remains inconclusive from these data if this aggregation is 
predominantly driven by said endosomal fusion or the inherent low aqueous solubility of 
individual paclitaxel-functionalized AuNPs. In light of these findings, additional efforts 
may be required to minimize the aggregation of particles. Future studies will focus on 
imaging cells at various times in an effort to observe the endocytic process at earlier time 
points to better understand the cellular uptake of metallic nanoparticles. 
Nevertheless, the results of this experiment demonstrate the susceptibility of 
hybrid system 23 to be readily internalized by cells followed by confinement in 
endosome-like structures. If indeed the interior of these vesicular structures is acidic, 
then rapid and efficient hydrolysis of the hydrazone linker is expected, leading to an 
effective method for the intracellular delivery of paclitaxel based on a AuNP carrier. 
While encouraging, these results do not guarantee cellular activity for our hybrid system. 
Once cleaved, the paclitaxel endgroups will remain trapped in the interior of endosomes 
unless they are able to passively diffuse through the endosomal membrane. However, 
passive diffusion is believed to be the primary mechanism for entry of hydrophobic drugs 
into cells, so it is hypothesized that any demonstrated cytotoxicity observed for hybrid 23 
can be attributed to the ability of released drug to subsequently escape the endosomal 
compartment. 
5.4. pH-Mediated Release of Surface-Bound PTX from AuNPs. 
To investigate the susceptibility of linker degradation under endosomal 
conditions, hydrazone-containing compound 23 was incubated at 37°C in acidic media 
(pH 5.0). Aliquots were removed at predetermined time intervals and analyzed by GPC 
112 
for free PTX content. Interestingly, the release profile illustrated in Figure 2 reveals a 
similar trend to those observed for both PTX-2' succinate and dithiodibutyrate systems in 
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Figure 3. Release profile observed for the appearance of PTX upon incubation of 23 in an acidic 
environment. 
that the majority of release occurs during the first 2-3 hours. In fact, 50% of the total 
released material is observed during the first 2 hours, indicative of acid-catalyzed 
hydrolysis in an environment representative of that found within the endosome. These 
data suggest that upon cellular uptake and encapsulation, the system is capable of 
undergoing rapid degradation, thereby releasing the therapeutic payload. While cleavage 
of the terminal PTX groups has been demonstrated under relevant conditions, it is 
important to note that the cellular toxicity must then be recovered upon enzymatic 
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hydrolysis of the remaining C-2' pyruvate ester. However, as described in preceding 
chapters, hydrolysis and subsequent reclamation of toxicity for paclitaxel intermediates 
esterified at the C-2' postion is efficient in the absence of the HEG linker. 
& 23 PTX2* pyruvate 21 
H 
Scheme 3. Illustration depicting the acid hydrolysis of surface-bound PTX releasing PTX-2' 
pyruvate. 
5.5. In vitro Growth Inhibition of MCF-7 Cells 
Having confirmed both the intracellular destination of drug loaded AuNPs as well 
as the efficient release of terminal PTX groups under conditions associated with the 
endosomal environment, the antiproliferative capabilities of hydrazone-containing 
nanoparticles 23 were investigated. To this end, cellular assays were performed to 
compare the ability of our new PTX-AuNP system to inhibit cell growth relative to the 
parent drug. Briefly, MCF-7 cells were treated over a range of concentrations (based on 
equivalent PTX content) for all samples and relative cell survival was measured 72 hours 
post treatment following the MTT protocol. Additionally, compound 21 was also 
analyzed as it represents the agent released from the gold surface upon degradation of the 
hydrazone linker. Results of these experiments are shown in Figure 4. 
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Figure 4. Observed growth inhibition against MCF-7 breast cancer cells for final product 23 and 
PTX-2' pyruvate compared to that of free paclitaxel. 
As previously described, commercially available paclitaxel exhibits high potency 
towards inhibiting cell growth as evidenced by an IC50 value of approximately 4 nM. 
Interestingly, intermediate 21 displays a virtual retention of toxicity (ICso= 9 nM), 
providing additional evidence of the high susceptibility of PTX-2' esters to enzymatic 
hydrolysis. Coupled with the results of our cellular uptake studies as well as those 
obtained in release experiments, the potent inhibitory qualities of 21 confirm the 
usefulness of a hydrazone strategy towards effecting intracellular drug delivery based on 
a AuNP carrier. Perhaps the most exciting result obtained from this study is the 
demonstrated ability of 23 to inhibit cell growth, effecting 50% inhibition at a 
concentration of approximately 12 nM. Also noteworthy, the difference in IC50 values 
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for 21 and 23 (3 nM) suggests that hydrolysis of the hydrazone linker is indeed rapid 
upon cellular internalization. Additionally, the 8 nM increase in the IC50 value for 23 
compared to that of free paclitaxel suggests the near quantitative delivery of surface 
bound drug. Interestingly, the increased activity observed for the final product suggests 
that once cleaved, free paclitaxel does not remain confined in the endosome. It is 
hypothesized that the release drug is capable of passive diffusion through the endosomal 
membrane in a manner analogous to that of commercially available paclitaxel diffusing 
through the external cell membrane. 
5.6. Effect of PTX-AuNP 23 on Tumor Regression in vivo. 
Given the demonstrated success of 23 towards the intracellular delivery and 
subsequent reclamation of cellular toxicity for the potent chemotherapeutic paclitaxel, 
experiments were prepared to test the ability of our AuNP system to incite tumor 
regression in a living model. Prior to these in vivo experiments, cellular toxicity of 23 
was confirmed independently by our collaborators on various head and neck cancer cell 
lines. Results of these experiments also revealed the toxicity of our hybrid system to be 
comparable to that of free paclitaxel. Tumor regression was then observed following an 
orthotopic xenograft model in which nude mice were injected orally with OCS-19 
luciferase cells to introduce tumors on the tongue. Approximately two weeks post tumor 
injection, groups of mice were separated based on homogenized tumor volume and 
treated with various concentrations of paclitaxel and PTX-AuNP 23. Additionally, bare 
AuNPs as well as the solubilizing agent cremophor EL (1:1 w/v mixture of 
cremophonEtOH) were analyzed for inherent toxicity and compared to the untreated 
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control group. A total of 4 treatments (q= weekly in mg/kg PTX/mass of mouse) were 
carried out while observing the effect on tumor volume. 
Initial experiments were focused towards measuring the systemic toxicity of our 
PTX-AuNP conjugate vs. free paclitaxel, the results of which are shown in figure 6 
below. Overall, the data show a 50% survival rate for mice treated with 23 when 
compared to both free paclitaxel and the untreated control group after 50 days. 
Additionally, a 40% mortality rate is observed for the paclitaxel group after only 30 days 
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Figure 5. Survival rates of mice 50 days post tumor injection showing a 50% survival rate for 
the group treated with PTX-AuNP 23. 
while a 0% rate is observed for the PTX-AuNP group over the same time interval. These 
data are significant as they demonstrate a reduced systemic toxicity for our AuNP 
conjugate, suggesting a decreased ability of 23 to interact with normal tissue. This is not 
unexpected as it was initially hypothesized that the relative large size of a AuNP carrier 
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will be able to exploit the enhanced permeation and retention effect (EPR) of tumors 
hence, demonstrating an increased accumulation in tumors while exhibiting a lesser 
ability to escape circulation in normal tissue. The results of these initial animal studies 
clearly reveal that PTX-AuNP conjugate 23 is less systemically toxic than the free drug. 
If in fact the increased survival observed for mice treated with 23 was directly 
related to a selective accumulation of our AuNP hybrid inside the tumors, then an 
increased ability to incite tumor regression would also be expected. To answer this, 
average tumor volumes were recorded one week post treatment for each of the above 
groups in order to compare the ability of 23 to inhibit tumor growth compared to free 
paclitaxel. The results are shown in Figure 7. Unfortunately, the average size of tumors 
is nearly the same at all time points suggesting that the concentration selected for this 
study (5 mg PTX/kg mouse) was not significant enough to inhibit tumor growth in all 
groups. Additionally, the low number of test subjects (n = 5) in each group is statistically 
insignificant, preventing the generation of quantitatively meaningful data. However, a 
similar trend appears comparable to that observed in the aforementioned toxicity study. 
There were no data points recorded for either the untreated control or the paclitaxel group 
after 45 days as all test subjects had to be sacrificed due to a significant decline in health. 
This further supports the previous findings which demonstrate the nontoxic effects of 23 
on the overall health of the mice. 
Having determined the reduced toxicity associated with 23, a second animal study 
was conducted to more accurately establish the inhibitive effects on tumor growth 
compared to the free drug. For this study, luciferase imaging was employed in addition 
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Figure 6. Initial results from tumor regression studies. No regression was observed compared to 
the untreated group due to insufficient paclitaxel concentrations. Please note that these data were 
obtained via manual measurements of physical tumors. 
to manual measurements to observe the average size of tumors. To ensure tumor 
regression, paclitaxel equivalent doses were increased from 5 mg/kg mouse to 10 mg/kg 
mouse and 20 mg/kg mouse with tumor volumes being reported 40 days post tumor 
injection and upon 4 weekly treatments with the compounds of interest. Representative 
data shown in Figure 8 shows that at both concentrations PTX-AuNP 23 (e and f) 
exhibits a slight decrease in efficacy compared to that of the free drug (c and d). 
However, both AuNP concentrations demonstrate an increased ability to incite tumor 
regression over both control groups (Figure 7, a and b). Unfortunately, as in the previous 
experiment, the number of samples in each group (n = 6) is not statistically significant, 
decreasing the ability to quantify these results. Additionally, the low number of test 
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Figure 7. Manual measurements of tumor volume for mice treated with Cremophor EL (a), 
mercaptophenol-coated AuNPs (b), free paclitaxel 10 mg/kg (c), free paclitaxel 20 mg/kg (d), 
AuNP 23 10 mg/kg (e) and AuNP 23 20 mg/kg (f). 
subjects in each group greatly increases standard deviations and further complicates the 
attempts to quantify the data. However, we are encouraged by these results as it can be 
qualitatively concluded that our AuNP system maintains comparable activity to that 
exhibited by the free drug. Having demonstrated the significant advantage of our PTX-
AuNP system over the free drug regarding inherent systemic toxicity, this minimal loss in 
efficacy is acceptable. 
In addition to manually measuring tumor sizes, luciferase imaging allows for not 
only the visual inspection of tumors but also allows for direct measurement of volume 
based on a bioluminescence approach. Briefly, an active ingredient, luciferin, is injected 
into mice having tumors based on complementary luciferase cells. Once bound to these 
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Figure 8. Measured luciferin photon emission profiles for mice treated with Cremophor EL (a), 
mercaptophenol-coated AuNPs (b), free paclitaxel 10 mg/kg (c), free paclitaxel 20 mg/kg (d), 
AuNP 23 10 mg/kg (e) and AuNP 23 20 mg/kg (f). 
cells, luciferin emits photons which can be detected and quantified based on the intensity 
of photons emitted. An increase in luciferin intensity corresponds directly to an increased 
number of cells hence, increased tumor volume. Results from this analysis are depicted 
in Figures 8 and 9. Initially, the data obtained from measuring the concentration of 
emitted photons (Figure 8) reveals an increase in tumor regression for our AuNP system 
at a dose of 20 mg PTX/kg mouse compared to free drug while demonstrating a lesser 
ability to encourage tumor regression at the 10 mg/kg dose. Living images shown in 
Figure 9 illustrate a similar trend in that the group treated with our PTX-AuNP system 
displays a more favorable average tumor volume profile at the highest concentration 
tested. Unfortunately, as previously stated, the number of subjects in each group (n = 3-
6) is too small to be statistically significant and no quantitative data can be extracted from 
these observations. However, it is qualitatively conclusive from both in vivo experiments 
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Figure 9. Living luciferase images of mice treated with free paclitaxel 10 mg/kg (top, 
left), AuNP 23 10 mg/kg (top, right), free paclitaxel 20 mg/kg (bottom, left) and AuNP 
23 20 mg/kg (bottom, right). 
that our hydrazone based delivery system exhibits comparable activity to free paclitaxel 
in animal models. Perhaps most important from these experiments is the observed lack 
of systemic toxicity observed for 23 when compared to the free drug. This finding is 
significant as reducing the negative side effect profile associated with chemotherapy is a 
primary goal of the medical field. Additional in vivo experiments are underway and will 
be reported in due course. 
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5.7. Conclusions 
Provided the intrinsic lack of biological activity observed in previous AuNP based 
systems, it was imperative to investigate the location of drug loaded nanoparticles upon 
cellular internalization. Based on literature reports describing the inherent intracellular 
fate of surface modified gold nanoparticles, we developed a delivery system featuring an 
acid labile hydrazone moiety. Our observation of the confinement of 23 to endosomal 
compartments supports the potential of an intracellular delivery strategy based on an acid 
labile hydrazone linker. Additionally, the release of terminal PTX groups was found to 
be greatly influenced under acidic conditions (pH 5) comparable to the interior of 
endosomes. However, the proof-of-principle for this system was demonstrated through 
the ability of the hybrid system to inhibit cell growth. The results of cell culture 
experiments confirm the ability of 23 to quantitatively release paclitaxel inside a living 
cell based on endogenous cellular processes, resulting in reactivation and subsequent 
cytotoxicity of the parent compound. 
Results from initial animal studies reveal a significant reduction in systemic 
toxicity for our PTX-AuNP conjugate. Additionally, we were able to qualitatively 
confirm that our hybrid system exhibits comparable efficacy towards tumor regression as 
free paclitaxel. These findings are important as the primary goal of chemotherapy is the 
selective targeting of tumors for drug delivery towards minimizing the negative side 
effects associated with treatment. Future studies will focus on the in vivo distribution of 
23 in hopes of confirming the ability to passively accumulate inside of tumors as well as 
structural modifications to further increase selective delivery of paclitaxel to solid 
tumors. 
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5.8. Experimental Methods and Materials 
Unless otherwise stated, all starting materials were obtained from commercial 
suppliers and used without further purification. Cells and cell culture supplies were 
purchased from American Type Tissue Culture (ATCC) and processed via supplier 
directions. Absorbance values for MTT analysis were recorded using a GeneMate 
ELx800 absorbance reader (BioTek) at 570 nm while using a 690 nm filter as a cutoff. 
*H NMR were recorded in CDCI3 using a Bruker 400 MHz spectrometer. Size Exclusion 
Chromatography (SEC) analysis was performed on a Waters Breeze 1515 series liquid 
chromatograph equipped with a dual X absorbance detector (Waters 2487), automatic 
injector, and three styrogel columns (HR1, HR3, HR4) using linear polystyrene standards 
for the calibration curve and tetrahydrofuran (THF) as the mobile phase. 
Thermogravimetric analysis was performed on a TA Instruments TGA Q50. 3.0-6.0 mg 
samples were placed in platinum sample pans and heated under argon atmosphere at a 
rate of 10 °C/min to 100 °C and held for 30 minutes to completely remove residual 
solvent. Samples were then heated to 700 °C at a rate of 10 °C/min. TEM and HRTEM 
imaging was performed on a JEOL 21 OOF transmission electron microscope operating at 
200 kV accelerating voltage. Samples were drop cast from dilute solutions of 10 % THF 
in CH2CI2 onto carbon-coated TEM grids and allowed to dry in open air. Centrifugal 
filters (2 mL capacity) Ultrafree®-CL containing regenerated cellulose membranes with a 
molecular weight cut-off of 30,000 g/mol were purchased from Fisher Scientific Inc. 4-
(N, N-dimethylamino)-pyridinium-4-toluenesulfonate (DPTS) was prepared by mixing 
saturated THF solutions of N,N-dimethylaminopyridine (DMAP) (1 equiv) and p-
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toluenesulfonic acid monohydrate (1 equiv) at room temperature. The precipitate was 
filtered, washed several times with THF, and dried under vacuum. 
5.8.1. Synthetic methods. 
Paclitaxel 2' pyruvate (21). To a solution of 100 mg of paclitaxel in 4 mL of CH2CI2 
were added 60 mg (1.5 equiv) of DPTS and 13 mg (1.3 equiv) of pyruvic acid. Under 
vigorous stirring, 75 mg (5 equiv) of the coupling agent DIPC were added to catalyze 
ester formation. Upon addition of DIPC the colorless solution immediately becomes 
yellow in color and progresses to a dark orange color as the reaction continues. Near 
complete consumption of starting PTX is observed after 2-3 hours as evidenced by TLC 
and the reaction is quenched upon removal of DPTS via three water extractions. The 
mixture is then dried over Na2SC>4 and solvent reduced under vacuum while DIPC is 
subsequently removed by precipitating the crude product from hexanes. Compound 17 is 
then further isolated by column chromatography eluting with a 4:1 mixture (v/v) of 
EtOAc:hexanes providing 98 mg (91% yield) of a white powder. Rf=0.60. 'H NMR 
(CDCI3) 6 1.14 (s, 3H), 1.25 (s, 3H), 1.69 (s, 3H), 1.80-1.96 (broad, 4H), 2.05 (s, 3H), 
2.23 (s, 3H), 2.45 (m, 1H), 3.83 (d, 1H), 4.10 (m, 1H), 4.21 (d, 1H), 4.32 (d, 1H), 4.45 
(m, 1H), 5.00 (d, 1H), 5.50 (d, 1H), 5.69 (d, 1H), 6.05 (d, 1H), 6.20-6.30 (m, 2H), 7.04 
(d, 1H), 7.33-7.48 (m, 10H), 7.63 (m, 1H), 7.74 (d, 2H), 8.16 (d, 2H). 
Hydrazidotetraethylene glycol amide glutarate. 15 mg of glutaric anhydride were first 
placed in an 8 mL glass vial and dissolved in a minimal amount of THF prior to dilution 
with 1.5 mL of CH2CI2 (a few drops of THF are required as the anhydride has limited 
solutbility in methylene chloride). Amide formation is immediate upon the dropwise 
addition of a solution containing, 50 mg (1.0 equiv) of commercially available 
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aminotetraethylene glycol t-boc hydrazide in 0.50 mL of CH2CI2. Upon GPC analysis, 
the reaction was determined to be complete after one hour due to the existence of only 
one product peak. Solvent was then removed under vacuum and prepared for structural 
analysis. 'H NMR (CDC13) 5 1.44 (s, 9H)a, 1.96 (m, 2H), 2.30-2.43 (broad, 4H), 2.54 (m, 
2H), 3.40 (m, 2H), 3.63 (m, 12H), 3.72 (m, 4H), 7.60 (s, 1H), 8.94 (s, 1H). a?-boc 
protons. 
Compound 22. Prior to hydrazone formation, the t-Boc protected hydrazide linker is 
first treated with a solution of 20% TFA in CH2CI2. After 30 minutes, TFA and residual 
solvent are removed under vacuum pressure and the resulting colorless oil dissolved in 
1.5 mL of THF. Following the liberation of the t-Boc group, 50 mg of PTX-2' pyruvate 
21 are dissolved in 1 mL of THF and added to the hydrazide linker solution. Hydrazone 
formation is then catalyzed by the addition of 1 -2 drops of TFA. Progress of the reaction 
is monitored via TLC (4:1 EtOAc:hexanes) based on the decrease in UV intensity of 
compound 21 (Rf=0.60) and the appearance of a highly UV active spot with an Rf value 
of 0. Upon completion, TFA and solvent are removed under high vacuum and the 
residual product precipitated from hexanes. Excess 21 is then removed by washing the 
precipitate with a 10% solution of EtOAc in hexanes until it is no longer detectable in 
TLC (3-4 washes). Typical yields for this reaction are moderate (approximately 70% 
based on the starting linker). Rf=0. *H NMR (CDC13) 5 1.14 (s, 3H), 1.25 (s, 3H), 1.69 
(s, 3H), 1.80-1.96 (broad, 6H), 2.05 (s, 3H), 2.23 (s, 3H), 2.30-2.40 (broad, 4H) 2.45 (m, 
1H), 2.55 (m, 2H), 3.45 (m, 2H), 3.65 (m, 12H), 3.83 (m, 5H), 4.20 (m, 1H), 4.30 (d, 
1H), 4.45 (m, 1H), 4.98 (d, 1H), 5.50-5.70 (m, 2H), 6.00 (d, 1H), 6.20-6.30 (m, 2H), 
7.25-7.55 (m, 11H), 7.60 (m, 1H), 7.74 (d, 2H), 8.16 (d, 2H). 
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Au(PTX)n (23). Preactivation of the carboxyl terminated intermediate is achieved upon 
the addition of 20 mg of DIPC to a 3 mL solution of methylene choloride containing 15 
mg of 22 and 25 mg of DPTS. Immediately following the addition of DIPC, a solution of 
5 mg of mercaptophenol-functionalized AuNPs in 0.30 mL of DMF is added to the above 
mixture. The reaction is monitored by GPC and additional amounts of 22 are added in 3-
5 mg aliquots until saturation of nanoparticles is complete based on the sharpness and 
quality of the product signal in GPC. After 3-4 hours, the reaction is quenched upon 
DPTS removal via three extractions with DI water followed by drying of the crude 
solution over Na2SC>4. Methylene chloride is removed under vacuum and the residual 
product is then diluted in DMF and placed on regenerated cellulose membrane filters 
(Millipore MWCO 30 kDa) and subjected to 3 rounds of centrifugation at 40 minutes 
each before being analyzed for purity by GPC. Following complete removal of all low 
molecular weight impurities, 23 is diluted with CH2CI2 and DMF is removed via water 
extractions. The product solution is again dried over Na2SC>4 and the final product 
precipitated from hexanes and dried under high vacuum leaving 14 mg of a light brown 
powder. 'H NMR (CDCI3) 5 1.14 (s, 3H), 1.25 (s, 3H), 1.69 (s, 3H), 1.80-1.96 (broad, 
6H), 2.05 (s, 3H), 2.23 (s, 3H), 2.30-2.40 (broad, 4H) 2.45 (m, 1H), 2.55 (m, 2H), 3.45 
(m, 2H), 3.65 (m, 12H), 3.83 (m, 5H), 4.20 (m, 1H), 4.30 (d, 1H), 4.45 (m, 1H), 4.98 (d, 
1H), 5.50-5.70 (m, 2H), 6.00 (d, 1H), 6.20-6.30 (m, 2H), 7.25-7.55 (m, 11H), 7.60 (m, 
1H), 7.74 (d, 2H), 8.16 (d,2H). 
5.8.2. Cellular Uptake of PTX-AuNP 23 
MCF-7 cells were plated in 6 well plates and allowed to proliferate until 
approximately 80-90% confluent. Once optimal confluency was reached, increasing 
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concentrations of 23 were added to each well in order to ensure sufficient uptake for 
imaging (up to 100 ug/mL). Following 12 hours of incubation with drug-functionalized 
nanoparticles, the cells were fixed with a solution of gluteraldehyde and sent to our 
collaborators for further processing. Cells were then imaged by transmission electron 
microscopy (TEM). 
5.8.3. pH-Mediated Release of Surface-Bound Paclitaxel 
In an 8 mL screw cap vial, a 1 mL solution of 10 mg of 23 in DMSO was diluted 
with cell culture grade water to a final volume of 6 mL. The vial was then placed in an 
oil bath (37°C) and stirred slowly at 200 rpm. The pH was adusted to 5 by addition of 1 
M HC1 to the solution (typically 1-2 drops). 1 mL aliquots of the reaction mixture were 
then taken at predetermined time points and combined with 1.5 mL of CH2CI2. After 
vigorous stirring for 5 minutes, the layers were allowed to separate and the organic 
fraction analyzed for free PTX content by GPC (40 uL injections). Peak areas were 
measured for each sample and plotted against time. 
5.8.4. MTT Assay 
MCF-7 breast cancer cells were plated in 96-well plates at a concentration of 
4,000 cells/well (100 uL/well) and allowed to attach for 24 hours. After successful 
attachment, 100 uL of media containing the compounds of interest and free paclitaxel (1, 
2, 5, 10, 25, 50, 100 and 500 nM with respect to paclitaxel) were added to each well, with 
each sample concentration having 5 replicates. 72 hours post treatment, 25 uL of yellow 
MTT solution (5 mg/mL in PBS) were added to each well and incubated at 37°C for 3-4 
hours to allow for sufficient conversion to the blue formazan precipitate. Next, the media 
was removed followed by the addition of 100 uL of DMSO to dissolve the blue formazan 
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metabolite. Upon agitating the plates for 2 minutes, absorbance values were recorded 
using a plate reader (Gene Mate, BioTek) equipped with a 570 nm filter. 
5.8.5. In vivo Study 
OSC-19-Luc cells, from a human head and neck squamous cell carcinoma 
(HNSCC) cell line stably transfected with a luciferase reporter, were harvested from 
subconfluent cultures by trypsinization and washed. The orthotopic nude mouse model of 
squamous cell carcinoma of the oral tongue was established by injecting OSC-19-Luc 
(5 x 104) cells suspended in 30 uL of serum-free Dulbecco modified Eagle medium into 
the mouse tongue as described previously.1 When tumors of a similar size (4-10 mm3) 
were established they were randomized into 3 groups according to treatment (10-15 mice 
per group): no-treatment control, free taxol, and taxol gold nanoparticle (taxol-AuNP). 
Drugs were administered intravenously once a week at 10 mg/kg (according to the taxol). 
The mice were treated for 4 weeks. They were examined twice a week for tumor volume 
and weight loss. Tumor volume (V) was calculated using the formula V = (A)(B )w/6, 
where A is the longest dimension of the tumor and B is the dimension of the tumor 
perpendicular to A. Mice were sacrificed by carbon dioxide asphyxiation if they lost 
more than 20% of their preinjection body weight or became moribund. The remaining 
mice were killed at the completion of the experiment 6 weeks after treatment 
commenced. Necropsy was performed on the mice, with removal of tongue tumors and 
cervical lymph nodes. The cervical lymph nodes were also embedded in paraffin and 
sectioned, stained with hematoxylin-eosin, and evaluated for the presence of metastases. 
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Bioluminescence of the tongue tumors through standardized regions of interest 
was quantified using Living Images (Xenogen Corp, Alameda, California). Animals were 
anesthetized with 2% isoflurane (Abbott, Abbott Park, Illinois) before and during 
imaging. An aqueous solution of luciferin (Xenogen Corp) at 150 mg/kg in a volume of 
0.1 mL2 was injected intraperitoneally 5 minutes prior to imaging. Animals were imaged 
at a peak time of 10 minutes after luciferin injection via a IVIS 200 imaging system 
(Xenogen Corp). The photons emitted from the luciferase-expressing cells within the 
animal were quantified using the software program Living Image (Xenogen, Corp) as an 
overlay on IGOR software (WaveMetrics, Portland, Oregon). The photon flux was 
calculated for each mouse using a rectangular region of interest encompassing the head 
and neck region of the mouse in a dorsal position. Animals were imaged after 
xenografting immediately (day 0) and on an almost weekly basis. Before their use in vivo, 
the engineered OSC-19-Luc cells were confirmed to homogeneously express high levels 
of luciferase in vitro as monitored by the IVIS imaging system. 
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5.8.6. NMR Spectra for Intermediate and Final Compounds 
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Figure 10. 'H NMR spectrum of t-Boc hydrazide tetraethylene glycol glutarate. 
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Figure 11. *H NMR spectrum of paclitaxel 2' pyruvate 21. 
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Figure 12. 'H NMR spectrum of PTX 2' hydrazone tetraethylene glycol glutarate 22. 
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Chapter 6: Synthesis of Water Soluble Paclitaxel-Functionalized AuNPs 
6.1. Introduction 
Due to the inherent insolubility of paclitaxel in aqueous media, a synthetic 
strategy was developed towards the manufacturing of individually water soluble 
paclitaxel-AuNP conjugates. Primarily motivated by minimizing the use of the 
cremophor EL and ethanol mixture currently required for administration of paclitaxel, it 
is anticipated that the method described herein will exhibit several advantages in addition 
to increasing the water solubility of the drug, the first of which being a reduction in the 
allergic reactions associated with the cremophor EL/EtOH mixture. More specifically, 
this analogous structure will feature an increase in the number of hexaethylene glycol 
units on the gold surface, thereby decreasing interactions with biological processes such 
as opsonization and ultimately, RES clearance. As previously stated, a common motif in 
prodrug design is the employment of polyethylene glycol (PEG) chains to increase drug 
circulation times in the body as a result of increasing RES avoidance.1"4 Coupled with 
data obtained for our base paclitaxel-AuNP conjugate in preliminary animal studies, we 
hypothesize that an increase in circulation will directly relate to an increase in drug 
availability hence, increased tumor regression. 
6.2. Synthesis of Water Soluble Y-Shaped Paclitaxel-AuNP Conjugate 
The synthetic sequence reported here is a continuation of that employed in our 
initial scheme as described in chapter 2 of this thesis. Briefly, PTX-7-HEG intermediate 
6 is coupled to the surface of AuNPs in an exact 1:1 ratio with hexaethylene glycol 
through utilization of a Y-shaped strategy common in our lab for the synthesis of 
amphiphilic polymers. " This method allows for complete control over the final organic 
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structure, which is crucial for structural characterization of the target AuNP conjugate. 
As stated previously, it is this well-defined structure of our nanoparticle hybrid that 
allows for an accurate quantification of bound drug. Additionally, HEG was chosen over 
longer polyethylene glycol chains because it is a single molecule with a known molecular 
weight. Inclusion of higher molecular weight PEG polymers will no doubt greatly 
increase water solubility, but will also introduce polydispersity into the final structure 
therefore, decreasing our ability to accurately measure the content of paclitaxel. 
The current scheme begins with the synthesis of a Y-shaped core by coupling 
mono TBS-protected glutaric acid to phloroglucinol (1,3,5-trihydroxy benzene) under 
standard DIPC/DPTS conditions (Scheme 1). A large excess of trihydroxy benzene was 
used to influence the primary formation of mono-coupled product, which is then easily 
removed via DI water extractions prior to product purification on silica gel. The first arm 
of the Y-shaped intermediate is then complete upon the coupling of carboxyl-terminated 
intermediate 6 to one of the remaining hydroxyls of the TBS-
HO^ 
o o 
X X H O " ^ - / V - ^ v O T B S 
ft"" \ ^ 15equiv 
OH 
DIPC/DPTS 
CH2CI2, rt, 2 hr 
OTBS 
Scheme 1. Synthesis of the Y-shaped core featuring two free hydroxyls with which to couple 
each remaining arm. 
protected core (Scheme 2). Again, excess of the intermediate core is used to ensure 
coupling to only one of the free hydroxyl groups. The second arm of the Y-shaped 
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o o ?, rW^fottr 
o °o 
HO OBz O A c 
THB-GA-TBS 
10equiv 
HOAc, THF 
H2O,50°C _ 2 6 R = H 
Scheme 2. Synthesis of the Y-shaped molecule by attaching both PTX-linker and HEG. 
compound is then completed by attaching mono TIPS hexaethylene glycol glutarate 
followed by the subsequent selective carboxyl deprotection of 25 via acetic acid 
treatment at elevated temperatures. Carboxyl-terminated 26 is then coupled to the 
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surface of mercaptophenol-functionalized particles as previously described followed by 
deprotection of remaining silyl groups using HF/pyridine (70:30 v/v) providing the final 
paclitaxel-AuNP conjugate 28. 
Scheme 3. Covalent grafting of Y-shaped molecule to the surface of 2 nm AuNPs followed by 
subsequent silyl group removal with HF. 
6.3. Water Solubility of Y-Shaped Paclitaxel-AuNP Conjugate 
Having synthesized the Y-shaped product 28, we wanted to test the solubility of 
individual particles in an aqueous environment compared to that of previously 
synthesized product 8. Briefly, both conjugates were dissolved in a minimal amount of 
DMSO before being further diluted with approximately 4 mL of DI water. The resulting 
AuNP solutions were then placed in dialysis bags (MWCO 10 kDa) and dialyzed against 
DI water to completely remove DMSO. Samples of each solution were then prepared 
and imaged by transmission electron microscopy (TEM) as shown in Figure 1. 
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Figure 1. Representative TEM images showing the aggregation of AuNP 8 in water (left) and 
water soluble drug-loaded particles 28 (right). 
Surprisingly, our initial paclitaxel-AuNP conjugate 8 shows the ability to 
assemble into micellar structures which exhibit a reasonably high level of water stability. 
In fact, these suspensions appear to be stable for up to a week prior to separation and 
subsequent settling. This result was not expected as hexaethylene glycol alone does not 
significantly increase the water solubility of paclitaxel prior to attachment to the surface 
of gold nanoparticles. However, TEM images of 28 (Figure 1, right) reveal the complete 
water solubility of individual drug-loaded particles as evidenced by the lack of observed 
assembly or aggregation. This drastic increase in water solubility can be attributed to the 
ability of paclitaxel to collapse onto the gold surface, while allowing the extension of an 
adjacent HEG moiety, which is unique to this Y-shaped strategy. Furthermore, this result 
demonstrates that a much longer PEG chain is not required to impart water solubility to 
free paclitaxel as has been reported.9 
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Figure 2. An aqueous suspension of self-assembled 8 in water (left) and an aqueous solution of 
28 in water (right). The haze observed for the suspension of 8 is characteristic of light scattering 
caused by self-assembled structures. Note that "H20' is written in reverse on the backside of the 
vial so the reader must look through the solution. 
Visual inspection of the two solutions also supports the findings observed from 
TEM analysis. As depicted in Figure 2 (left), a hazy suspension of self-assembled 
particles results upon the dialysis of 8 in DI water, which is characteristic of the 
scattering of light caused by self-assembled structures. However, an aqueous solution of 
28 (Figure 2, right) appears clear, representative of a true molecular solution. 
6.4. Conclusions 
The need to increase the water solubility of paclitaxel has been addressed in this 
chapter through the incorporation of a unique, Y-shaped intermediate featuring an 
additional HEG moiety into the structure of our paclitaxel-AuNP conjugate. Also 
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important, this strategy allows for the inclusion of additional HEG groups without 
sacrificing the ability to fully characterize the final hybrid structure. This work is 
significant as it negates the requirement of the solubulizing agent cremophor EL currently 
used to administer paclitaxel, which is associated with its own negative side effects. In 
addition to reducing the toxic effects of cremophor EL, it is hypothesized that application 
of this strategy with our biologically active hydrazone system will result in increased 
circulation times in the body and therefore, greater tumor inhibition compared to that 
observed for the previously described conjugate 23. Interestingly, application of this y-
shaped strategy could be extended towards the incorporation of additional targeting 
ligands while maintaining complete control over ligand-to-paclitaxel ratio. Further 
increasing versatility, this method could see future utility as a means to introduce 
additional agents in an attempt to produce a AuNP system designed to simultaneously 
administer multiple drugs analogous to combination therapy. Cell culture experiments 
will be studied and reported in due course. 
6.5. Experimental Methods and Materials 
Unless otherwise stated, all starting materials were obtained from commercial 
suppliers and used without further purification. Cells and cell culture supplies were 
purchased from American Type Tissue Culture (ATCC) and processed via supplier 
directions. Absorbance values for MTT analysis were recorded using a GeneMate 
ELx800 absorbance reader (BioTek) at 570 nm while using a 690 nm filter as a cutoff. 
' H NMR were recorded in CDCI3 using a Bruker 400 MHz spectrometer. Size Exclusion 
Chromatography (SEC) analysis was performed on a Waters Breeze 1515 series liquid 
chromatograph equipped with a dual X absorbance detector (Waters 2487), automatic 
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injector, and three styrogel columns (HR1, HR3, HR4) using linear polystyrene standards 
for the calibration curve and tetrahydrofuran (THF) as the mobile phase. 
Thermogravimetric analysis was performed on a TA Instruments TGA Q50. 3.0-6.0 mg 
samples were placed in platinum sample pans and heated under argon atmosphere at a 
rate of 10 °C/min to 100 °C and held for 30 minutes to completely remove residual 
solvent. Samples were then heated to 700 °C at a rate of 10 °C/min. TEM and HRTEM 
imaging was performed on a JEOL 21 OOF transmission electron microscope operating at 
200 kV accelerating voltage. Samples were drop cast from dilute solutions of 10 % THF 
in CH2CI2 onto carbon-coated TEM grids and allowed to dry in open air. Centrifugal 
filters (2 mL capacity) Ultrafree®-CL containing regenerated cellulose membranes with a 
molecular weight cut-off of 30,000 g/mol were purchased from Fisher Scientific Inc. 4-
(N, N-dimethylamino)-pyridinium-4-toluenesulfonate (DPTS) was prepared by mixing 
saturated THF solutions of N,N-dimethylaminopyridine (DMAP) (1 equiv) and p-
toluenesulfonic acid monohydrate (1 equiv) at room temperature. The precipitate was 
filtered, washed several times with THF, and dried under vacuum. 
6.5.1. Synthetic Methods 
Hexaethylene glycol monotriisopropylsilyl ether. To a solution of 500 mg of 
hexaethylene glycol (HEG) and 120 mg (1.1 equiv) of imidazole in 4 mL of DMF were 
slowly added 340 mg (1 equiv) of triisopropylsilyl chloride (TIPSC1). After allowing the 
reaction to proceed for 3 hours, the solution was diluted with an equal volume of CH2CI2 
and washed with DI water three times to remove DMF, imidazole and any unreacted 
HEG. The crude product was then isolated via column chromatography eluting with a 
27% solution of THF in methylene chloride providing approximately 300 mg (36% yield) 
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of a colorless oil. Rf=0.50. 'H NMR (CDC13) 8 1.07 (s, 18H)a, 3.64 (s, 22H), 3.82 (m, 
2H). aTIPS protons. 
Monotriisopropyl silyl hexaethylene glycol glutarate. 300 mg of hexaethylene glycol 
triisopropylsilyl ether and 1.0 g (13 equiv) of glutaric anhydride were placed in a round 
bottom flask and dissolved in 15 mL of DMF. Upon component dissolution, 170 mg (2 
equiv) of DMAP were added to accelerate coupling. After 8 hours, the solution was 
diluted with approximately 30 mL of CH2CI2 and transferred to a separatory funnel. 
DMF and DMAP were initially removed via 3 extractions with DI water followed by 6 
extractions with a saturated solution of NaHCC>3 to remove excess glutaric anhydride. 
The remaining solution was dried over Na2SC>4 prior to solvent removal under vacuum 
pressure yielding 258 mg (68%) of a colorless oil. 'H NMR (CDC13) 5 1.07 (s, 18H)a, 
1.94 (m, 2H), 2.33-2.43 (broad, 4H), 3.64 (s, 22H), 3.82 (m, 2H). aTIPS protons. 
Mono /-butyldimehtylsilyl glutaric acid. To a round bottom flask containing 3.0 g 
glutaric acid in 40 mL of DMF were added 2.0 g (1 equiv) of the base morpholine. The 
flask was then equipped with a rubber stopper before the dropwise syringe addition of 
4.37 g (1 equiv) of f-butyldimethylsilyl chloride (TBSC1). After 5 minutes, the reaction 
mixture was diluted with approximately 100 mL of methylene chloride and transferred to 
a separatory funnel. DMF and morpholine were removed via three extractions with DI 
water and the remaining solution dried over Na2S04. The desired product was 
subsequently purified over a silica gel column providing approximately 1.43 g of a 
colorless oil (21%). R<=0.50 in 4% THF in CH2C12. *H NMR (CDC13) 5 0.92 (s, 9H)b, 
1.93 (m, 2H), 2.41 (m, 4H). bTBS protons. 
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Trihydroxy benzene mono f-butyldimethylsilyl glutarate. In a small round bottom 
flask were dissolved 150 mg of monoTBS glutaric acid in 10 mL of CH2CI2. To this 
solution were added 1.0 g (15 equivalents) of phloroglucinol (1,3,5-trihydroxy benzene) 
as well as 200 mg of DPTS. Once all of the above were in solution, 350 mg (5 
equivalents) of DIPC were added to initiate coupling. The reaction was complete after 1 -
2 hours as determined by TLC (10% THF in CH2CI2, Rf=0.65) and was quenched upon 
extracting DPTS with water. The product was then isolated via column chromatography 
eluting with 10% THF solution in methylene chloride leaving 184 mg (89% yield) of a 
colorless oil. *H NMR (CDCI3) 5 0.93 (s, 9H)b, 2.01 (m, 2H), 2.44 (m, 2H), 2.59 (m, 
2H), 6.10 (s, 2H), 6.17 (s, 1H). bTBS protons. 
Compound 24. To a 4 mL solution containing 20 mg of previously described 
intermediate 6 and 10 mg of DPTS in methylene chloride were dissolved 75 mg (14 
equiv) of trihydroxy benzene mono /-butyldimethylsilyl glutarate. Once all of the above 
were in solution, 10 mg (5 equiv) of DIPC were added to catalyze anhydride formation. 
After one hour, GPC analysis shows an almost quantitative conversion to the desired 
product and only approximately 1 -2% formation of the bifunctionalized contaminiant. 
The reaction was quenched upon washing the organic fraction three times with DI water. 
The product was then isolated over a silica gel column eluting with a 5:1 v/v mixture of 
EtOAc and hexanes. Rf=0.60. Isolated 22 mg (88% yield) of a white powder. 'HNMR 
(CDCI3) 5 -0.29 (s, 3H)b, -0.02 (s, 3H)b, 0.80 (s, 9H)b, 1.05-1.20 (broad, 9H)b, 1.21 (m, 
3H), 1.82-1.98 (m, 9H), 2.01 (m, 2H), 2.15 (broad, 4H), 2.33-2.45 (m, 7H), 2.58 (broad, 
6H), 3.66-3.70 (m, 24H), 3.95 (d, 1H), 4.23 (broad, 5H), 4.35 (d, 1H), 4.95 (d, 1H), 5.65 
(t, 1H), 5.75 (m, 2H), 6.26 (broad, 2H), 6.40 (s, 1H), 6.49 (s, 1H), 6.52 (s, 1H), 7.11 (d, 
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1H), 7.33 (m, 3H), 7.43 (m, 4H), 7.52 (m, 3H), 7.62 (m, 1H), 7.75 (d, 2H), 8.13 (d, 2H). 
bTBS protons. 
Compound 25. 20 mg of 24 and 10 mg DPTS were first dissolved in 4 mL of CH2CI2 
followed by the addition of 10 mg (1.5 equiv) of mono triisopropylsilyl hexaethylene 
glycol glutarate. Again, coupling was initiated by the addition of 5 equivalents of DIPC. 
After 2 hours, GPC analysis revealed the complete conversion of starting 24 and the 
reaction was subsequently quenched upon removal of DPTS via water extractions. 
Interestingly, both DIPC and excess HEG linker were removed by precipitating the crude 
product from hexanes followed by two additional hexane washes leaving 22 mg of a 
white oil (85% Yield). *H NMR (CDC13) 5 -0.29 (s, 3H)b, -0.02 (s, 3H)b, 0.80 (s, 9H)b, 
1.05-1.20 (broad, 27H)a'b, 1.21 (m, 3H), 1.82-1.98 (m, 9H), 2.01 (m, 2H), 2.15 (broad, 
4H), 2.33-2.45 (m, 7H), 2.58 (broad, 6H), 3.66-3.70 (m, 48H), 3.95 (d, 1H), 4.23 (broad, 
5H), 4.35 (d, 1H), 4.95 (d, 1H), 5.65 (t, 1H), 5.75 (m, 2H), 6.26 (broad, 2H), 6.81 (s, 3H), 
7.11 (d, 1H), 7.33 (m, 3H), 7.43 (m, 4H), 7.52 (m, 3H), 7.62 (m, 1H), 7.75 (d, 2H), 8.13 
(d, 2H). aTIPS protons. bTBS protons. 
Compound 26. Compond 25 was dissolved in 2 mL of THF and placed in an 8 mL vial 
equipped with a screw cap. While stirring vigorously, 5.6 mL of HO Ac were added 
followed by the dropwise addition of 0.40 mL of DI H2O. The reaction mixture was 
placed in an oil bath (50°C) and allowed to proceed for at least 12 hours. The solution is 
then diluted with 15 mL of CH2CI2 and the organic fraction was washed three times with 
DI water to remove HOAc. The remaining solution was then dried over Na2S04 
followed by solvent reduction under vacuum pressure. The desired product was then 
isolated upon precipitation from hexane three times providing a white powder and used 
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without further purification. Quantitative yield. !H NMR (CDC13) 5 -0.29 (s, 3H)b, -0.02 
(s, 3H)b, 0.80 (s, 9H)b, 1.05-1.20 (broad, 18H)a, 1.21 (m, 3H), 1.82-1.98 (m, 9H), 2.01 
(m, 2H), 2.15 (broad, 4H), 2.33-2.45 (m, 7H), 2.58 (broad, 6H), 3.66-3.70 (m, 48H), 3.95 
(d, 1H), 4.23 (broad, 5H), 4.35 (d, 1H), 4.95 (d, 1H), 5.65 (t, 1H), 5.75 (m, 2H), 6.26 
(broad, 2H), 6.52 (s, 3H), 7.11 (d, 1H), 7.33 (m, 3H), 7.43 (m, 4H), 7.52 (m, 3H), 7.62 
(m, 1H), 7.75 (d, 2H), 8.13 (d, 2H). aTIPS protons. bTBS protons. 
Au(Y-shaped PTX TBS/TIPS)n (27). 15 mg of the above carboxyl-terminated Y-
shaped intermediate and 25 mg of DPTS were dissolved in 3 mL of methylene chloride, 
followed by the addition of 12 mg of DIPC. Upon anhydride activation, 0.30 mL of a 
DMF solution containing 5 mg of stock mercaptophenol-functionalized AuNPs were 
added and the coupling of 26 to the nanoparticle surface was monitored vial GPC. After 
approximately 3 hours, there were no visible changes in the GPC chromatograph 
suggesting completion of the reaction. DMF and DPTS were removed as previously 
described upon washing the organic solution three times with DI water. Methylene 
chloride was then removed under reduced pressure and the remaining crude mixture 
dissolved in DMF. The hybrid product was then purified via membrane centrifugation 
(Millipore, regenerated cellulose membrane with MWCO of 30 kDa). ]H NMR (CDCI3) 
5 -0.29 (s, 3H)b, -0.02 (s, 3H)b, 0.80 (s, 9H)b, 1.05-1.20 (broad, 18H)a, 1.21 (m, 3H), 
1.82-1.98 (m, 9H), 2.01 (m, 2H), 2.15 (broad, 4H), 2.33-2.45 (m, 7H), 2.58 (broad, 6H), 
3.66-3.70 (m, 48H), 3.95 (d, 1H), 4.23 (broad, 5H), 4.35 (d, 1H), 4.95 (d, 1H), 5.65 (t, 
1H), 5.75 (m, 2H), 6.26 (broad, 2H), 7.00 (s, 3H), 7.11 (d, 1H), 7.33 (m, 3H), 7.43 (m, 
4H), 7.52 (m, 3H), 7.62 (m, 1H), 7.75 (d, 2H), 8.13 (d, 2H). "TIPS protons. bTBS 
protons. 
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Au (Y-shaped PTX)„ (28). The synthetic sequence was complete upon the removal of 
the remaining silyl protecting groups. Deprotection was induced by the addition of 0.50 
mL of a mixture of HF in pyridine (70:30 v/v) to a 1.5 mL THF solution of 27 in a 
polypropylene vial. After 4 hours, the mixture was diluted with 4 mL of CH2CI2 and 
extracted three times with DI water and dried over Na2SC>4. The product was then 
precipitated from hexanes and any remaining silyl groups were removed via two 
additional hexane washes. 'H NMR (CDC13) 5 1.21 (m, 3H), 1.82-1.98 (m, 9H), 2.01 (m, 
2H), 2.15 (broad, 4H), 2.33-2.45 (m, 7H), 2.58 (broad, 6H), 3.66-3.70 (m, 48H), 3.95 (d, 
1H), 4.23 (broad, 5H), 4.35 (d, 1H), 4.95 (d, 1H), 5.65 (t, 1H), 5.75 (m, 2H), 6.26 (broad, 
2H), 6.85 (s, 3H), 7.11 (d, 1H), 7.33 (m, 3H), 7.43 (m, 4H), 7.52 (m, 3H), 7.62 (m, 1H), 
7.75 (d, 2H), 8.13 (d,2H). 
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6.5.2. NMR Spectra for Intermediate and Final Compounds 
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Figure 3. 'H NMR spectrum of mono fer/-butyldimethylsilyl glutarate. 
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Summary and Conclusions 
The work described in this thesis details the design of a novel AuNP carrier 
system featuring the covalent loading of a therapeutic agent capable of intracellular 
release as influenced by endogenous biological processes. This unique method is 
attractive in that the synthetic route employed here results in the production of a hybrid 
system suitable for direct structural analysis based on traditional analytical techniques. 
The ability to directly confirm the chemical structure as well as quantify the amount of 
bound drug is crucial as it allows for a greater understanding of biological efficacy. 
Specifically, initial efforts were focused on linking paclitaxel to the gold surface through 
esterification of the C-7 hydroxyl. Attachment at this position was motivated by the 
stability of C-7 esters to hydrolysis, thereby minimizing the possibility of premature drug 
dissociation. While introducing increased stability to the system, this paclitaxel-AuNP 
conjugate was found to exhibit virtually no ability to inhibit cell proliferation in cellular 
assays. However, the significance of this work lies in the successful development of the 
general synthetic blueprint for manufacturing future drug-AuNP conjugates as well as 
establishing the analytical protocol for their complete structural characterization. 
In an attempt to improve the cytotoxic profile of our hybrid system, analogous 
linker strategies were employed featuring esterification of the C-2' hydroxyl of paclixel. 
Known for an inherent susceptibility to esterase hydrolysis, C-2' esters effectively 
undergo rapid degradation in vitro, resulting in the release of the biologically active 
parent compound. PTX-2' succinate intermediates synthesized in this work were found 
to posses toxicity comparable to free drug confirming the potential utility of this prodrug 
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approach. In addition, the efficient release of terminal PTX groups from the gold surface 
was demonstrated upon incubating the paclitaxel-AuNP conjugate in the presence of 
enzyme containing serum. An alternative release strategy employed the incorporation of 
a disulfide moiety into the linker structure. Disulfide bonds are often employed in 
various prodrugs as they impart a predominantly intracellular mechanism of release as 
degradation is influenced by glutathione, which exists in significantly greater 
concentrations inside cells. Similarly, intermediates produced in this synthetic sequence 
also displayed comparable activity to free paclitaxel. Upon incubation of the final AuNP 
conjugate in the presence of GSH, a rapid and efficient dissociation of bound PTX groups 
was observed. Interestingly, glutathione exhibited a greater affinity for the gold surface 
compared to the disulfide bond, demonstrating the accessibility of the gold surface to 
biological molecules. While the aforementioned AuNP conjugates display the ability to 
effectively release surface bound PTX under ideal conditions, they fail to inhibit cell 
growth in cytoxicity studies. However, provided the demonstrated efficient release of 
bound drug in the presence of intracellular agents, the lack of toxicity is attributed to the 
inclusion of the Au core. These observations proved critical in the development of our 
final system as they suggest the rational design of an effective nanoparticle delivery 
system will result from an investigation into the inherent intracellular fate of AuNPs. 
Consistent with literature reports, our independent investigation into the cellular 
uptake of drug loaded AuNPs reveals an essentially quantitative confinement of 
internalized particles inside endosomal structures as evidenced by TEM imaging. Given 
that endosomes are more acidic relative to physiological pH, an alternative intracellular 
release strategy was employed featuring an acid-labile hydrazone functionality. In 
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addition to intermediate PTX compounds, the final hydrazone containing AuNP 
conjugate exhibited antiproliferative capabilities comparable to that of free paclitaxel. In 
fact, the observed IC5o value for PTX (4-5 nM) was only slightly lower than that 
observed for our final system (12 nM), suggesting the near quantitative delivery of active 
compound from our AuNP carrier. Preliminary in vivo studies are currently in progress 
focusing on the ability of this hydrazone containing AuNP conjugate to influence tumor 
regression in a living system. Initial results suggest a comparable ability to inhibit tumor 
growth when compared to free paclitaxel. However, a higher survival rate has been 
observed for mice treated with our drug loaded nanoparticles suggesting lower systemic 
toxicity. Further animal studies are required to obtain an increased understanding of 
PTX-AuNP systems in vivo and results from these studies will be reported in due course. 
Having established the strategy required for the successful intracellular delivery 
of therapeutic cargo based on a AuNP carrier, we wanted to address the low aqueous 
solubility associated with paclitaxel. Two methods were described detailing the 
incorporation of PEG into the hybrid structure, resulting in individually water soluble 
PTX-AuNP conjugates. This work is significant as it not only negates the requirement 
for the solubilizing agent cremophor EL, which is associated with the onset of 
hypersensitivity, but will also minimize the aggregation of particles observed in 
previously described cellular uptake studies. Additionally, it is hypothesized that 
nonaggregated particles may exhibit longer circulation times providing increased access 
to tumor tissue, while reducing rapid clearance via the reticuloendothelial system (RES). 
In conclusion, we have described a method for the synthesis of a unique drug 
delivery system based on the covalent attachment of drug molecules to the surface of 
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AuNPs. This work represents a significant contribution to the field of bionanomaterials 
as we have not only described a method for manufacturing a well-defined drug-
nanoparticle system, but have also incorporated a release mechanism complimentary to 
the inherent intracellular behavior of gold nanoparticles. The marriage of a hydrazone 
functionality with the endosomal fate of AuNPs results in a synthetically simple strategy 
for the quantitative delivery of paclitaxel. Finally, it is concluded that this AuNP-
hydrazone strategy can be applied towards the efficient intracellular delivery of a broad 
range of biologically active compounds. 
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